ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
2,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
3,1,Loss of libido,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
4,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4,2,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
4,3,Temporomandibular pain and dysfunction syndrome,Joint related disorders NEC,Joint disorders,Musc,N
5,1,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
5,2,Haemolytic anaemia,Anaemias haemolytic NEC,Haemolyses and related conditions,Blood,N
6,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
7,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
7,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
8,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
9,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
9,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
9,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
10,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
11,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
11,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
11,3,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
11,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
12,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
12,2,Blood triglycerides increased,Triglyceride analyses,Lipid analyses,Inv,N
13,1,Lichenoid keratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
14,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
15,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
15,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
16,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
16,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
16,3,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
16,4,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
16,5,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
16,6,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
16,7,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
16,8,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
16,9,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
16,10,Tearfulness,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
17,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
17,2,Streptococcal impetigo,Streptococcal infections,Bacterial infectious disorders,Infec,N
18,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
19,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
19,2,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
20,1,Dairy intolerance,Food malabsorption and intolerance syndromes (excl sugar intolerance),Food intolerance syndromes,Metab,N
20,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
21,1,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
21,2,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
22,1,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
23,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
24,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
24,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
24,3,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
25,1,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
26,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
27,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
27,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
28,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
29,1,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
29,2,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
30,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
30,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
31,1,Blood thyroid stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
31,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
32,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
32,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
33,1,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
33,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
34,1,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
34,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
34,3,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
35,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
35,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
35,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
36,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
36,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
37,1,Headache,Headaches NEC,Headaches,Nerv,N
37,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
37,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
37,4,Visual field defect,Visual field disorders,Vision disorders,Eye,N
38,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
38,2,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
38,3,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
39,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
40,1,Headache,Headaches NEC,Headaches,Nerv,N
40,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
40,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
41,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
41,2,Porphyria non-acute,Inborn errors of porphyrin metabolism,Metabolic and nutritional disorders congenital,Cong,N
42,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
42,2,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
42,3,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
42,4,Respiratory rate increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
43,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
44,1,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
44,2,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
44,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
45,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
45,2,Rash morbilliform,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
46,1,Erythema nodosum,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
46,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
46,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
46,4,Vasculitic rash,Skin vasculitides,Skin vascular abnormalities,Skin,N
47,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
47,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
48,1,Dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
48,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
48,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
48,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
49,1,Dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
50,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
50,2,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
51,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
51,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
51,3,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
52,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
52,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
52,3,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
52,4,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
53,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
53,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
54,1,Bone marrow disorder,Haematological disorders,Haematological disorders NEC,Blood,N
54,2,Granuloma,Inflammations,General system disorders NEC,Genrl,N
55,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
56,1,Conjunctival disorder,"Conjunctival structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
56,2,Lichenoid keratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
57,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
57,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
57,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
57,4,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
58,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
58,2,Seborrhoeic dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
59,1,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
59,2,Retinopathy proliferative,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
60,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
60,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
60,3,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
60,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
61,1,Cryoglobulinaemia,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
61,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
61,3,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
61,4,Raynaud's phenomenon,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
62,1,Raynaud's phenomenon,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
63,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
64,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
64,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
65,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
66,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
67,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
67,2,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
67,3,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
67,4,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
67,5,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
67,6,Cardiac murmur,Cardiac auscultatory investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
67,7,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
67,8,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
67,9,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
67,10,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
67,11,Tricuspid valve incompetence,Tricuspid valvular disorders,Cardiac valve disorders,Card,N
68,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
69,1,Polyarthritis,Arthropathies NEC,Joint disorders,Musc,N
69,2,Synovitis,Synovial disorders,Synovial and bursal disorders,Musc,N
70,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
71,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
71,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
71,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
71,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
71,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
71,6,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
72,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
73,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
73,2,Necrotising fasciitis,Muscle and soft tissue infections,Infections - pathogen unspecified,Infec,Y
73,3,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
74,1,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
75,1,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
75,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
76,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
76,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
76,3,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
76,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
77,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
77,2,Gastrointestinal cancer metastatic,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
77,3,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
77,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
77,5,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
77,6,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
78,1,Chromosome analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
78,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
78,3,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
78,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
79,1,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
79,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
79,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
80,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
81,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
82,1,Breast tenderness,Breast signs and symptoms,Breast disorders,Repro,N
83,1,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
84,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
84,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
84,3,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
85,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
85,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
85,3,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
85,4,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
85,5,Cardiac murmur,Cardiac auscultatory investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
85,6,Endocarditis bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
85,7,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
85,8,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
85,9,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
86,1,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
87,1,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
88,1,Lichenoid keratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
88,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
89,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
89,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
90,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
90,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
91,1,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
91,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
91,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
92,1,Hepatitis acute,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
92,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
93,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
93,2,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
93,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
94,1,Retinal detachment,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
94,2,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
95,1,Dental caries,Dental and periodontal infections and inflammations,Dental and gingival conditions,Gastr,N
95,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
95,3,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
95,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
95,5,Impaired healing,Healing abnormal NEC,Tissue disorders NEC,Genrl,N
95,6,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
95,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
95,8,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
95,9,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
95,10,Tooth loss,Tooth missing,Dental and gingival conditions,Gastr,N
95,11,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
96,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
97,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
97,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
97,3,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
97,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
97,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
98,1,Chronic fatigue syndrome,Asthenic conditions,General system disorders NEC,Genrl,N
98,2,Dental caries,Dental and periodontal infections and inflammations,Dental and gingival conditions,Gastr,N
98,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
98,4,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
98,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
98,6,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
99,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
99,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
100,1,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
100,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
101,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
102,1,Erythrodermic psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
103,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
103,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
103,3,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
103,4,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
103,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
103,6,Traumatic lung injury,Chest and respiratory tract injuries NEC,Injuries NEC,Inj&P,N
104,1,Complication associated with device,Complications associated with device NEC,Complications associated with device,Genrl,N
105,1,Acute respiratory distress syndrome,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
105,2,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
105,3,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
106,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
107,1,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
107,2,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
108,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
109,1,Fungal endocarditis,Fungal infections NEC,Fungal infectious disorders,Infec,N
110,1,Oral lichenoid reaction,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
111,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
111,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
112,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
112,2,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
112,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
112,4,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
112,5,Hyperuricaemia,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
112,6,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
112,7,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
112,8,Urine output decreased,Urinary tract function analyses NEC,Renal and urinary tract investigations and urinalyses,Inv,N
113,1,Encephalitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
114,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
114,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
115,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
115,2,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
116,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
117,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
117,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
118,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
118,2,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
118,3,Mean cell volume abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
118,4,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
118,5,Serum ferritin decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
119,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
119,2,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
119,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
119,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
119,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
120,1,Hyperplasia,Trophic disorders,Tissue disorders NEC,Genrl,N
121,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
121,2,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
121,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
122,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
123,1,Affective disorder,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
123,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
123,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
123,4,"Delusional disorder, unspecified type",Delusional disorders,Schizophrenia and other psychotic disorders,Psych,N
123,5,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
123,6,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
124,1,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
124,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
125,1,Cytogenetic abnormality,Chromosomal abnormalities NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
125,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
125,3,Leukaemia,Leukaemias NEC,Leukaemias,Neopl,N
125,4,Leukaemic retinopathy,Leukaemias NEC,Leukaemias,Neopl,N
125,5,Myeloblast count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
125,6,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
126,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
126,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
126,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
126,4,Gastrointestinal oedema,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
126,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
127,1,Cytogenetic abnormality,Chromosomal abnormalities NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
127,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
127,3,Leukaemia,Leukaemias NEC,Leukaemias,Neopl,N
127,4,Leukaemic retinopathy,Leukaemias NEC,Leukaemias,Neopl,N
127,5,Myeloblast count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
127,6,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
128,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
128,2,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
128,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
129,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
129,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
130,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
131,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
131,2,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
131,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
132,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
132,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
132,3,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
132,4,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
133,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
133,2,Gastrointestinal motility disorder,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
133,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
134,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
134,2,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
135,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
135,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
135,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
136,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
136,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
136,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
137,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
137,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
138,1,Sideroblastic anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
139,1,Tumour haemorrhage,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
140,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
140,2,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
141,1,Blast cell crisis,Leukaemias acute NEC,Leukaemias,Neopl,Y
142,1,Exfoliative rash,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
142,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
143,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
143,2,Cholecystitis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
144,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
145,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
146,1,Parotitis,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
147,1,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
148,1,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
148,2,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
148,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
149,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
150,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
150,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
151,1,Porphyria non-acute,Inborn errors of porphyrin metabolism,Metabolic and nutritional disorders congenital,Cong,N
152,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
153,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
153,2,Sunburn,Radiation injuries,Injuries by physical agents,Inj&P,N
154,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
154,2,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
154,3,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
154,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
154,5,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
155,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
155,2,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
155,3,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
155,4,Myalgia,Muscle pains,Muscle disorders,Musc,N
156,1,Lichen planus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
157,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
158,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
159,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
160,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
161,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
161,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
161,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
161,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
162,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
162,2,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
162,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
163,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
164,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
165,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
165,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
165,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
166,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
166,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
167,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
168,1,Erythema nodosum,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
168,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
169,1,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
169,2,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
170,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
171,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
171,2,Headache,Headaches NEC,Headaches,Nerv,N
171,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
171,4,Skin tightness,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
172,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
173,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
174,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
174,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
174,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
175,1,Growth retardation,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
176,1,Exfoliative rash,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
176,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
177,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
177,2,Retinal artery occlusion,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
178,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
178,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
179,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
179,2,Laryngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
179,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
179,4,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
179,5,Oedema mouth,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
179,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
179,7,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
180,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
180,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
180,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
180,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
180,5,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
180,6,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
180,7,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
181,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
181,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
181,3,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
181,4,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
181,5,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
181,6,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
181,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
181,8,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
182,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
183,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
184,1,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
185,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
185,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
185,3,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
185,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
186,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
187,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
187,2,Barrett's oesophagus,Gastrointestinal mucosal dystrophies and secretion disorders,Gastrointestinal conditions NEC,Gastr,N
187,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
187,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
187,5,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
187,6,Oesophageal ulcer,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
188,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
189,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
190,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
190,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
191,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
191,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
192,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
192,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
192,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
192,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
192,5,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
192,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
192,7,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
192,8,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
193,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
194,1,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
194,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
194,3,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
194,4,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
194,5,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
194,6,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
194,7,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
194,8,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
194,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
195,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
195,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
196,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
197,1,Eye discharge,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
197,2,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
198,1,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
199,1,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
199,2,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
200,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
200,2,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
201,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
202,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,Y
202,2,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
203,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
203,2,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
204,1,Furuncle,Staphylococcal infections,Bacterial infectious disorders,Infec,N
204,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
204,3,Lichen planus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
205,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
206,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
206,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
206,3,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
206,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
206,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
206,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
207,1,Activated partial thromboplastin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
207,2,Ammonia decreased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
207,3,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
207,4,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
207,5,Blood creatine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
207,6,Blood fibrinogen decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
207,7,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
207,8,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
207,9,Fibrin D dimer increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
207,10,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
207,11,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
207,12,Hepatic encephalopathy,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
207,13,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
207,14,Hepatic necrosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
207,15,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
207,16,Intracranial pressure increased,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
207,17,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
207,18,Liver transplant,Hepatic therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
207,19,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
207,20,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
207,21,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
207,22,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
207,23,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
207,24,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
207,25,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
208,1,Creatinine renal clearance decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
208,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
209,1,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
210,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
210,2,Physical disability,Disability issues,Lifestyle issues,SocCi,N
211,1,Vitreous haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
212,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
212,2,Glare,Visual disorders NEC,Vision disorders,Eye,N
212,3,Macular oedema,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
212,4,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
212,5,Visual acuity tests abnormal,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
213,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
213,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
213,3,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
213,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
213,5,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
213,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
213,7,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
214,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
214,2,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
214,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
215,1,Musculoskeletal pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
215,2,Patellofemoral pain syndrome,Joint related disorders NEC,Joint disorders,Musc,N
216,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
217,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
217,2,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
218,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,Y
219,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
219,2,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
219,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
220,1,Abdominal sinus repair,Abdominal therapeutic procedures NEC,Gastrointestinal therapeutic procedures,Surg,N
220,2,Abdominal wall operation,Abdominal therapeutic procedures NEC,Gastrointestinal therapeutic procedures,Surg,N
220,3,Gastrointestinal fistula,Gastrointestinal fistulae,Gastrointestinal conditions NEC,Gastr,N
220,4,Ileostomy closure,Small intestine therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
220,5,Impaired healing,Healing abnormal NEC,Tissue disorders NEC,Genrl,N
220,6,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
220,7,Skin lesion removal,Skin lesion excisions,Skin and subcutaneous tissue therapeutic procedures,Surg,N
221,1,Brachydactyly,Musculoskeletal and connective tissue disorders of limbs congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
222,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
222,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
223,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
223,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
224,1,Vitreous haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
225,1,Acute generalised exanthematous pustulosis,Pustular conditions,Epidermal and dermal conditions,Skin,N
225,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
226,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
227,1,Hypovolaemic shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,Y
227,2,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
227,3,Renal amyloidosis,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
228,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
228,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
228,3,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
229,1,Congenital hand malformation,Musculoskeletal and connective tissue disorders of limbs congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
229,2,Pilonidal cyst congenital,Skin and subcutaneous tissue disorders congenital NEC,Skin and subcutaneous tissue disorders congenital,Cong,N
230,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
230,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
231,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
232,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
232,2,Respiratory tract infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
233,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
234,1,Meningioma,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
235,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
235,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
235,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
235,4,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
235,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
236,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
236,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
237,1,Gastrectomy,Gastric therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
237,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
238,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
238,2,Transfusion,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
239,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
239,2,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
239,3,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
240,1,Myeloid leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
241,1,Dermatitis exfoliative generalised,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
242,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,Y
243,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
244,1,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
244,2,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
244,3,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
244,4,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
245,1,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
245,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
246,1,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
246,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
246,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
247,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
247,2,Retroviral infection,Retroviral infections,Viral infectious disorders,Infec,N
248,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
248,2,Headache,Headaches NEC,Headaches,Nerv,N
248,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
248,4,Toothache,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
249,1,Anencephaly,Cerebral disorders congenital,Neurological disorders congenital,Cong,N
249,2,Exposure via body fluid,Pathways and sources of exposure,"Exposures, chemical injuries and poisoning",Inj&P,N
250,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
251,1,Micrognathia,"Musculoskeletal and connective tissue disorders of face, neck and jaw congenital",Musculoskeletal and connective tissue disorders congenital,Cong,N
251,2,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
252,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
252,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
253,1,Finger deformity,Extremity deformities,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
254,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
254,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
255,1,Leukaemia recurrent,Leukaemias NEC,Leukaemias,Neopl,N
256,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
256,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
256,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
256,4,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
256,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
256,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
257,1,Abdominal neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
257,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
257,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
257,4,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
258,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
258,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
258,3,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
259,1,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
260,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
260,2,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
261,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,Y
261,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
261,3,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
262,1,Headache,Headaches NEC,Headaches,Nerv,N
263,1,Cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
264,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
265,1,Chest X-ray abnormal,Respiratory tract and thoracic imaging procedures,Respiratory and pulmonary investigations (excl blood gases),Inv,N
265,2,Computerised tomogram abnormal,Imaging procedures NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
265,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
265,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
265,5,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
266,1,Eye movement disorder,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
266,2,Eyelid oedema,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
266,3,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
266,4,Lacrimal gland enlargement,"Lid, lash and lacrimal structural disorders","Anterior eye structural change, deposit and degeneration",Eye,N
266,5,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
266,6,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
267,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
267,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
267,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
268,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
269,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
269,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
269,3,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
270,1,Blood creatine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
270,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
270,3,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
271,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
271,2,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
271,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
271,4,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
271,5,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
271,6,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
271,7,Pericarditis,Noninfectious pericarditis,Pericardial disorders,Card,N
271,8,Presyncope,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
271,9,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
272,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
272,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
272,3,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
272,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
272,5,Pain in jaw,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
272,6,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
272,7,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
272,8,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
272,9,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
272,10,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
273,1,Conjunctival oedema,"Conjunctival infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
274,1,Angiocentric lymphoma,Angiocentric lymphomas,Lymphomas non-Hodgkin's T-cell,Neopl,Y
274,2,Chest X-ray abnormal,Respiratory tract and thoracic imaging procedures,Respiratory and pulmonary investigations (excl blood gases),Inv,N
274,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
274,4,Epstein-Barr virus infection,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
274,5,Lymphopenia,Leukopenias NEC,White blood cell disorders,Blood,N
274,6,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
274,7,Pleuritic pain,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
274,8,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
274,9,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
275,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
275,2,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
276,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
276,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
276,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
277,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
278,1,Arteriosclerosis coronary artery,Coronary artery disorders NEC,Coronary artery disorders,Card,N
278,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
278,3,Left ventricular failure,Left ventricular failures,Heart failures,Card,Y
278,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
279,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
280,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
280,2,Erythema nodosum,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
281,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
281,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
281,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
282,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
282,2,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
282,3,Hypogonadism,Endocrine abnormalities of gonadal function NEC,Endocrine disorders of gonadal function,Endo,N
283,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
284,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
284,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
285,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
286,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
287,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
287,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
288,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
289,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
289,2,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
290,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
290,2,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
291,1,Lichenoid keratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
291,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
291,3,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
292,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
292,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
292,3,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
292,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
292,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
292,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
292,7,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
292,8,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
293,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
294,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,Y
295,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
295,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
295,3,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
296,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
296,2,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
297,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
297,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
297,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
297,4,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
297,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
297,6,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
297,7,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
297,8,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
298,1,Blood prolactin increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
298,2,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
299,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
300,1,Melanosis,Hyperpigmentation disorders,Pigmentation disorders,Skin,N
301,1,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
301,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
302,1,Bell's palsy,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
302,2,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
303,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
303,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
304,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
304,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
304,3,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
304,4,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
304,5,Myalgia,Muscle pains,Muscle disorders,Musc,N
304,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
304,7,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
305,1,Exfoliative rash,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
305,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
305,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
306,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
307,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
307,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
308,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
308,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
308,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
309,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
309,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
309,3,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
309,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
310,1,Colorectal cancer,Colorectal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
311,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
312,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
312,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
312,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
313,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
313,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
313,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
313,4,Respiratory arrest,Breathing abnormalities,Respiratory disorders NEC,Resp,N
313,5,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
314,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
314,2,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
314,3,Ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
315,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
315,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
315,3,Incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
316,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
316,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
316,3,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
316,4,Hyperaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
316,5,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
316,6,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
316,7,Mean cell volume abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
316,8,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
316,9,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
317,1,Coombs direct test negative,Blood grouping and cross-matching analyses,Haematology investigations (incl blood groups),Inv,N
317,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
317,3,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
317,4,Haemolytic anaemia,Anaemias haemolytic NEC,Haemolyses and related conditions,Blood,N
317,5,Haptoglobin decreased,Haem metabolism analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
318,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
318,2,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
318,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
319,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
319,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
319,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
319,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
319,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
319,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
320,1,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
321,1,Abortion induced,Induced abortions,Obstetric and gynaecological therapeutic procedures,Surg,N
322,1,Abortion induced,Induced abortions,Obstetric and gynaecological therapeutic procedures,Surg,N
323,1,Decreased activity,Asthenic conditions,General system disorders NEC,Genrl,N
323,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
324,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
324,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
325,1,Macular oedema,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
325,2,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
326,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
327,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
327,2,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
328,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
328,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
328,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
329,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
329,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
329,3,Lung neoplasm,Respiratory tract and pleural neoplasms malignancy unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
329,4,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
329,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
329,6,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
330,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
330,2,Paralysis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
331,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
331,2,Anal incontinence,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
331,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
332,1,Anti-thyroid antibody positive,Thyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
332,2,Blood thyroid stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
332,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
332,4,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
332,5,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
333,1,Gastric cancer,Gastric neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
334,1,Gastric cancer,Gastric neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
335,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
336,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
336,2,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
336,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
336,4,Transplant,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
337,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
337,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
337,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
338,1,Headache,Headaches NEC,Headaches,Nerv,N
338,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
338,3,Tunnel vision,Neurologic visual problems NEC,Neurological disorders of the eye,Nerv,N
339,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
339,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
339,3,Spondylolisthesis,Spine and neck deformities,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
340,1,Abdominal mass,Abdominal findings abnormal,Gastrointestinal signs and symptoms,Gastr,N
340,2,Gastrointestinal carcinoma,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
340,3,Laparotomy,Abdominal therapeutic procedures NEC,Gastrointestinal therapeutic procedures,Surg,N
341,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
341,2,Disseminated intravascular coagulation,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
341,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
341,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
341,5,Tongue haemorrhage,Tongue disorders,Tongue conditions,Gastr,N
342,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
342,2,Anal incontinence,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
342,3,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
342,4,Cluster headache,Headaches NEC,Headaches,Nerv,N
342,5,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
342,6,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
342,7,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
342,8,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
342,9,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
342,10,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
342,11,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
342,12,Poor quality sleep,Dyssomnias,Sleep disorders and disturbances,Psych,N
342,13,Restless legs syndrome,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
342,14,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
342,15,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
342,16,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
342,17,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
343,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
344,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
344,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
345,1,Leukaemia recurrent,Leukaemias NEC,Leukaemias,Neopl,N
345,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
346,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
347,1,Hepatic necrosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
347,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
348,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
349,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
350,1,Non-small cell lung cancer,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,Y
351,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
351,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
351,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
352,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
352,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
352,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
352,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
352,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
353,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
353,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
353,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
353,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
354,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
354,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
354,3,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
354,4,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
354,5,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
354,6,Hepatic necrosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
354,7,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
355,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
355,2,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
355,3,Abdominal neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
355,4,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
355,5,Blood follicle stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
355,6,Cachexia,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
355,7,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
355,8,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
355,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
355,10,Muscle atrophy,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
356,1,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
356,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
357,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
358,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
358,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
359,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
359,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
359,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
360,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
360,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
361,1,Cerebral atrophy,Structural brain disorders NEC,Structural brain disorders,Nerv,N
361,2,Cerebral ventricle dilatation,Structural brain disorders NEC,Structural brain disorders,Nerv,N
361,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
361,4,Vascular dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
362,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
362,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
362,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
363,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
363,2,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
363,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
363,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
363,5,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
363,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
363,7,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
363,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
364,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
364,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
365,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
365,2,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
365,3,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
365,4,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
365,5,Necrotising fasciitis,Muscle and soft tissue infections,Infections - pathogen unspecified,Infec,N
365,6,Streptococcal sepsis,Streptococcal infections,Bacterial infectious disorders,Infec,Y
365,7,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
366,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
367,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
367,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
368,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
368,2,Blast cell crisis,Leukaemias acute NEC,Leukaemias,Neopl,N
368,3,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
368,4,Chromosome analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
368,5,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
368,6,Lichen planus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
368,7,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
368,8,Reticulin increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
369,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
369,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
370,1,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
371,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
371,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
372,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
372,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
372,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
372,4,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
372,5,Hypervolaemia,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
373,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
373,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
373,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
373,4,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
374,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
374,2,Musculoskeletal pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
374,3,Nerve compression,Mononeuropathies,Peripheral neuropathies,Nerv,N
374,4,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
374,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
374,6,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
375,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
376,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
376,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
376,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
377,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
378,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
378,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
378,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
378,4,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
378,5,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
379,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
379,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
379,3,Coronary artery stenosis,Coronary artery disorders NEC,Coronary artery disorders,Card,N
379,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
379,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
379,6,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
379,7,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
380,1,Conjunctival cyst,Ocular cysts and polyps,Ocular neoplasms,Eye,N
380,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
380,3,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
380,4,Spinal osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
381,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
382,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
383,1,Ear discomfort,Ear disorders NEC,Aural disorders NEC,Ear,N
383,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
383,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
383,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
383,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
383,6,Stent placement,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
384,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
385,1,Haematotoxicity,Haematological disorders,Haematological disorders NEC,Blood,N
385,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
385,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
386,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
387,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
387,2,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
387,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
387,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
388,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
388,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
388,3,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
388,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
388,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
388,6,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
389,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
389,2,Atrioventricular block complete,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
389,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
389,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
389,5,Headache,Headaches NEC,Headaches,Nerv,N
390,1,Lichenoid keratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
390,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
391,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
391,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
391,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
391,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
391,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
391,6,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
392,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
392,2,Pharyngeal oedema,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
392,3,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
393,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
393,2,Exercise tolerance decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
393,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
393,4,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
394,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
394,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
395,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
395,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
395,3,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
395,4,Eyelid oedema,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
395,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
395,6,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
395,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
396,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
396,2,Ear pain,Ear disorders NEC,Aural disorders NEC,Ear,N
396,3,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
396,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
396,5,Headache,Headaches NEC,Headaches,Nerv,N
396,6,Laryngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
396,7,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
396,8,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
397,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
397,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
397,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
397,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
397,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
397,6,Eyelid oedema,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
397,7,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
397,8,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
397,9,Myalgia,Muscle pains,Muscle disorders,Musc,N
397,10,Myalgia,Muscle pains,Muscle disorders,Musc,N
397,11,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
397,12,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
398,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
398,2,Neoplasm recurrence,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
399,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
399,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
399,3,Breast tenderness,Breast signs and symptoms,Breast disorders,Repro,N
399,4,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
399,5,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
399,6,Exercise tolerance decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
399,7,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
400,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
400,2,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
400,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
400,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
400,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
400,6,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
400,7,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
400,8,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
401,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
401,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
401,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
401,4,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
401,5,Pelvic fracture,Pelvic fractures and dislocations,Bone and joint injuries,Inj&P,N
402,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
402,2,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
403,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
403,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
404,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
404,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
405,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
405,2,Ear pain,Ear disorders NEC,Aural disorders NEC,Ear,N
405,3,Headache,Headaches NEC,Headaches,Nerv,N
405,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
405,5,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
406,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
406,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
406,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
406,4,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
406,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
406,6,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
406,7,Overweight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
407,1,Glioblastoma,Glial tumours malignant,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
408,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
408,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
408,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
409,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
409,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
409,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
409,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
409,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
409,6,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
409,7,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
410,1,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
410,2,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
410,3,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
411,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
411,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
411,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
411,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
411,5,Eyelid oedema,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
411,6,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
411,7,Laryngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
411,8,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
411,9,Myalgia,Muscle pains,Muscle disorders,Musc,N
411,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
412,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
413,1,Tendon rupture,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
414,1,Chromosome analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
414,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
414,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
414,4,High frequency ablation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
414,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
415,1,Muscle disorder,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
415,2,Tendon disorder,Tendon disorders,"Tendon, ligament and cartilage disorders",Musc,N
416,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
416,2,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
416,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
416,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
417,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
417,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
417,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
417,4,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
417,5,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
418,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
418,2,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
419,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
419,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
419,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
419,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
419,5,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
419,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
419,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
420,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
421,1,Ankle fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
422,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
422,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
423,1,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
423,2,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
424,1,Coombs test negative,Blood grouping and cross-matching analyses,Haematology investigations (incl blood groups),Inv,N
424,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
424,3,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
424,4,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
424,5,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
425,1,Full blood count increased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
425,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
425,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
426,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
426,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
427,1,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
427,2,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
427,3,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
427,4,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
428,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
428,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
428,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
428,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
429,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
429,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
429,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
430,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
430,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
431,1,Gastrointestinal carcinoma,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
432,1,Meningocele,Central nervous system disorders congenital NEC,Neurological disorders congenital,Cong,Y
432,2,Stillbirth,Stillbirth and foetal death,Abortions and stillbirth,Preg,N
433,1,Abortion induced,Induced abortions,Obstetric and gynaecological therapeutic procedures,Surg,Y
433,2,Cleft palate,Palate disorders congenital,Gastrointestinal tract disorders congenital,Cong,N
433,3,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
433,4,Polydactyly,Musculoskeletal and connective tissue disorders of limbs congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
434,1,Coarctation of the aorta,Great vessel disorders congenital,Cardiac and vascular disorders congenital,Cong,N
434,2,Congenital nose malformation,Nasal disorders congenital,Respiratory disorders congenital,Cong,N
434,3,Congenital pharyngeal anomaly,Pharyngeal disorders congenital,Respiratory disorders congenital,Cong,N
434,4,Dandy-Walker syndrome,Cerebral disorders congenital,Neurological disorders congenital,Cong,N
434,5,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
434,6,Gastroschisis,Gastrointestinal tract disorders congenital NEC,Gastrointestinal tract disorders congenital,Cong,N
434,7,Ventricular septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
435,1,Exomphalos,Gastrointestinal tract disorders congenital NEC,Gastrointestinal tract disorders congenital,Cong,N
435,2,Scoliosis,Spine and neck deformities,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
436,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
436,2,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
436,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
436,4,Wolff-Parkinson-White syndrome,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
437,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
437,2,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
437,3,Headache,Headaches NEC,Headaches,Nerv,N
437,4,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
437,5,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
437,6,White blood cell count,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
438,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
438,2,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
439,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
440,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
440,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
441,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
441,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
441,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
441,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
441,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
442,1,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
442,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
442,3,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
442,4,Tubulointerstitial nephritis,Nephritis NEC,Nephropathies,Renal,N
443,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
443,2,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
443,3,Hepatic necrosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
443,4,Hepatocellular injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
443,5,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
443,6,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
444,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
444,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
444,3,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
445,1,Acute respiratory distress syndrome,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
445,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
445,3,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
445,4,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
445,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
445,6,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
445,7,Hyperuricaemia,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
445,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
445,9,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
445,10,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
445,11,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
445,12,Peritonitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
445,13,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
445,14,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
445,15,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
445,16,Urine output decreased,Urinary tract function analyses NEC,Renal and urinary tract investigations and urinalyses,Inv,N
446,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
447,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
447,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
447,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
447,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
447,5,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
447,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
448,1,Coombs test negative,Blood grouping and cross-matching analyses,Haematology investigations (incl blood groups),Inv,N
448,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
448,3,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
448,4,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
448,5,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
449,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
449,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
449,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
449,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
450,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
450,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
451,1,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
452,1,Cholecystectomy,Biliary tract and gallbladder therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
452,2,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
453,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
454,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
454,2,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
454,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
455,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
456,1,Congenital anomaly,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
456,2,Exomphalos,Gastrointestinal tract disorders congenital NEC,Gastrointestinal tract disorders congenital,Cong,N
456,3,Hemivertebra,Musculoskeletal and connective tissue disorders of spine congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
456,4,Kidney duplex,Renal disorders congenital,Renal and urinary tract disorders congenital,Cong,N
456,5,Poor weight gain neonatal,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
456,6,Pulmonary hypoplasia,Pulmonary and bronchial disorders congenital,Respiratory disorders congenital,Cong,N
456,7,Shoulder deformity,Trunk deformities,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
456,8,Single functional kidney,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
457,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
458,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
458,2,Sperm concentration decreased,Fertility analyses and other reproductive function procedures,Reproductive organ and breast investigations (excl hormone analyses),Inv,N
459,1,Leukaemia recurrent,Leukaemias NEC,Leukaemias,Neopl,N
459,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
460,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
460,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
461,1,Leg amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
461,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
462,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
462,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
462,3,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
462,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
462,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
463,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
463,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
464,1,Breast disorder,Breast disorders NEC,Breast disorders,Repro,N
464,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
464,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
465,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
466,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
466,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
467,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
467,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
468,1,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
469,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
469,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
470,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
470,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
470,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
470,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
471,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
471,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
471,3,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
471,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
472,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
472,2,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
472,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
472,4,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
472,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
472,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
473,1,Generalised oedema,Oedema NEC,General system disorders NEC,Genrl,N
473,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
473,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
473,4,Nephritis,Nephritis NEC,Nephropathies,Renal,N
473,5,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
473,6,Protein urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
473,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
474,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
475,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
476,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
476,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
476,3,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
476,4,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
477,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
477,2,Generalised oedema,Oedema NEC,General system disorders NEC,Genrl,N
477,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
477,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
477,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
478,1,Bundle branch block left,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
478,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
479,1,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
479,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
479,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
480,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
480,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
481,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
482,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
482,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
483,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
483,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
483,3,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
484,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
485,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
485,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
485,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
485,4,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
486,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
486,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
487,1,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
488,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
488,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
488,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
488,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
488,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
489,1,Blast cell crisis,Leukaemias acute NEC,Leukaemias,Neopl,N
489,2,Cytogenetic abnormality,Chromosomal abnormalities NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
489,3,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
489,4,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
489,5,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
490,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
490,2,Systemic mastocytosis,Haematologic neoplasms NEC,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
491,1,Agranulocytosis,Neutropenias,White blood cell disorders,Blood,N
491,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
491,3,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
492,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
493,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
493,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
493,3,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
494,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
494,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
495,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
495,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
495,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
496,1,Gastrointestinal necrosis,Gastrointestinal necrosis and gangrene (excl gangrenous hernia),Gastrointestinal vascular conditions,Gastr,Y
497,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
497,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
497,3,Blood calcium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
497,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
497,5,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
497,6,Blood urea decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
497,7,Ear swelling,Ear disorders NEC,Aural disorders NEC,Ear,N
497,8,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
497,9,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
497,10,Hepatic lesion,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
497,11,High frequency ablation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
497,12,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
497,13,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
497,14,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
497,15,Protein total decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
497,16,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
497,17,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
497,18,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
497,19,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
498,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
498,2,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
498,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
499,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
499,2,Liver transplant,Hepatic therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
500,1,Non-small cell lung cancer,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
501,1,Non-small cell lung cancer,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
502,1,Gene mutation identification test positive,Gene analyses,Cytogenetic investigations and genetic analyses,Inv,N
502,2,Periorbital swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
502,3,Retinal artery occlusion,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
502,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
503,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
503,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
504,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
504,2,Tumour haemorrhage,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
504,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
505,1,Thrombophlebitis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
506,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
506,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
507,1,Telangiectasia,Telangiectasia and related conditions,Skin vascular abnormalities,Skin,N
508,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
508,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
508,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
508,4,Histology abnormal,Histopathology procedures NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
508,5,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
509,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
510,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
510,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
510,3,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
510,4,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
511,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
512,1,Headache,Headaches NEC,Headaches,Nerv,N
512,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
513,1,Generalised oedema,Oedema NEC,General system disorders NEC,Genrl,N
514,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
515,1,Atrial flutter,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
515,2,Atrioventricular block,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
515,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
516,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
516,2,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
516,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
517,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
518,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
518,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
518,3,Drug level fluctuating,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
519,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
519,2,Rib fracture,Thoracic cage fractures and dislocations,Bone and joint injuries,Inj&P,N
520,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,Y
521,1,Alcohol interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
521,2,Chromosome analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
521,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
521,4,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
522,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
522,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
523,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
523,2,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
523,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
523,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
523,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
523,6,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
524,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
524,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
525,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
526,1,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
526,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
527,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
528,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
528,2,Allogenic stem cell transplantation,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
528,3,Graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
528,4,Photopheresis,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
529,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
529,2,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
530,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
530,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
530,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
531,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
531,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
532,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
532,2,Drug level decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
533,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
533,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
534,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
535,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
535,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
535,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
535,4,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
536,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
537,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
537,2,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
538,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
538,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
538,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
538,4,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
538,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
539,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
540,1,Acute coronary syndrome,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
540,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
541,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
541,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
541,3,Echocardiogram abnormal,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
541,4,Left ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
541,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
542,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
543,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
544,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
544,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
544,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
545,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
545,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
546,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
546,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
546,3,Myoglobinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
547,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
547,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
547,3,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
547,4,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
547,5,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
547,6,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
547,7,Pathological fracture,Fractures NEC,Fractures,Musc,N
547,8,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
548,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
548,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
548,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
548,4,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
548,5,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
548,6,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
549,1,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
549,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
549,3,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
549,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
549,5,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
549,6,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
550,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
550,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
550,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
551,1,Encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
551,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
552,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
552,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
552,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
552,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
553,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
554,1,Cyst,Mass conditions NEC,Tissue disorders NEC,Genrl,N
554,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
554,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
555,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
556,1,Sexual dysfunction,Sexual function and fertility disorders NEC,Sexual function and fertility disorders,Repro,N
557,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
557,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
558,1,Left ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
558,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
559,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
559,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
559,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
559,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
560,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
560,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
560,3,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
560,4,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
560,5,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
560,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
561,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
561,2,Kawasaki's disease,Arterial infections and inflammations,Vascular infections and inflammations,Vasc,N
562,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
562,2,Liver transplant,Hepatic therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
563,1,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
563,2,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
564,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
564,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
564,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
565,1,Chromosome analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
566,1,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
567,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
567,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
567,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
567,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
568,1,Chromosome analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
568,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
568,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
569,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
570,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
571,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
572,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
572,2,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
573,1,Leukaemia recurrent,Leukaemias NEC,Leukaemias,Neopl,N
573,2,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
574,1,Dermatitis exfoliative generalised,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
575,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
576,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
576,2,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
577,1,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
578,1,Cardiogenic shock,Heart failures NEC,Heart failures,Card,N
578,2,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,Y
578,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
578,4,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
578,5,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
579,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
580,1,Carcinoid syndrome,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
580,2,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
580,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
580,4,Leukaemia recurrent,Leukaemias NEC,Leukaemias,Neopl,N
580,5,Malabsorption,Malabsorption syndromes,Malabsorption conditions,Gastr,N
581,1,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
582,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
582,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
582,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
582,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
582,5,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
582,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
582,7,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
583,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
583,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
583,3,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
584,1,Blood pressure abnormal,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
584,2,Uveitis,"Iris and uveal tract infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
585,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
585,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
585,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
585,4,Metastasis,Metastases to unknown and unspecified sites,Metastases,Neopl,N
585,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
586,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
586,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
586,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
586,4,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
586,5,Intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
586,6,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
586,7,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
586,8,Therapy cessation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
587,1,Open angle glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
588,1,Open angle glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
588,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
589,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
590,1,Ileostomy,Small intestine therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
591,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
592,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
592,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
593,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
594,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
594,2,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
595,1,Blood disorder,Haematological disorders,Haematological disorders NEC,Blood,N
596,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
596,2,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
597,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
598,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
599,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
599,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
599,3,Hepatectomy,Hepatic therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
599,4,High frequency ablation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
599,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
599,6,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
600,1,Laryngeal cancer,Laryngeal neoplasms malignant,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
600,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
601,1,Vitreous disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
602,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
602,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
602,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
603,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
603,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
603,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
603,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
603,5,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
604,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
604,2,Benign ovarian tumour,Ovarian neoplasms benign,Reproductive neoplasms female benign,Neopl,N
605,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
605,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
605,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
605,4,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
606,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
606,2,Hernia repair,Hernia repairs,Gastrointestinal therapeutic procedures,Surg,N
606,3,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
607,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
608,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
608,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
608,3,Tumour perforation,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
609,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
609,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
609,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
609,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
609,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
610,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
610,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
610,3,Temporal lobe epilepsy,Partial complex seizures,Seizures (incl subtypes),Nerv,N
611,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
611,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
611,3,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
611,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
611,5,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
611,6,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
612,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
612,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
612,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
612,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
612,5,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
613,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
613,2,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
613,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
614,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
614,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
614,3,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
614,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
614,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
614,6,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
614,7,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
614,8,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
614,9,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
614,10,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
614,11,Eye infection,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
614,12,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
614,13,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
614,14,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
614,15,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
614,16,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
614,17,Frustration tolerance decreased,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
614,18,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
614,19,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
614,20,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
614,21,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
614,22,Livedo reticularis,Skin vasomotor conditions,Skin vascular abnormalities,Skin,N
614,23,Loss of libido,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
614,24,Myalgia,Muscle pains,Muscle disorders,Musc,N
614,25,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
614,26,Peripheral circulatory failure,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
614,27,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
614,28,Scratch,Skin injuries NEC,Injuries NEC,Inj&P,N
614,29,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
614,30,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
614,31,Therapeutic response shortened,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
614,32,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
615,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
615,2,Chronic myeloid leukaemia transformation,Leukaemias chronic myeloid,Leukaemias,Neopl,N
616,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
616,2,Chronic myeloid leukaemia transformation,Leukaemias chronic myeloid,Leukaemias,Neopl,N
617,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
618,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
619,1,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
619,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
620,1,Gene mutation identification test positive,Gene analyses,Cytogenetic investigations and genetic analyses,Inv,N
620,2,Leukaemia recurrent,Leukaemias NEC,Leukaemias,Neopl,N
620,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
621,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
621,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
622,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
622,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
623,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
623,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
624,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
624,2,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
625,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
625,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
625,3,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
625,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
625,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
625,6,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
626,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
627,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
628,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
628,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
628,3,Drug level decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
628,4,Gene mutation identification test positive,Gene analyses,Cytogenetic investigations and genetic analyses,Inv,N
629,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
629,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
629,3,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
629,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
629,5,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
629,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
629,7,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
629,8,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
630,1,Chromosome analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
630,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
630,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
630,4,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
631,1,Dental care,Dental and gingival therapeutic procedures,Head and neck therapeutic procedures,Surg,N
631,2,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
631,3,Palatal oedema,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
632,1,Congenital hand malformation,Musculoskeletal and connective tissue disorders of limbs congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
632,2,Congenital skin dimples,Skin and subcutaneous tissue disorders congenital NEC,Skin and subcutaneous tissue disorders congenital,Cong,N
632,3,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
633,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
633,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
634,1,Paternal exposure timing unspecified,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
635,1,Anencephaly,Cerebral disorders congenital,Neurological disorders congenital,Cong,N
635,2,Paternal exposure timing unspecified,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
636,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
636,2,Gastrointestinal tube insertion,Gastrointestinal therapeutic procedures NEC,Gastrointestinal therapeutic procedures,Surg,N
636,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
637,1,Vitreous haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
638,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
638,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
638,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
638,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
639,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
639,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
639,3,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
639,4,Bedridden,Disability issues,Lifestyle issues,SocCi,N
639,5,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
639,6,Bradyphrenia,Thinking disturbances,Disturbances in thinking and perception,Psych,N
639,7,Breast enlargement,Breast disorders NEC,Breast disorders,Repro,N
639,8,Breast tenderness,Breast signs and symptoms,Breast disorders,Repro,N
639,9,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
639,10,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
639,11,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
639,12,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
639,13,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
639,14,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
639,15,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
639,16,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
639,17,Headache,Headaches NEC,Headaches,Nerv,N
639,18,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
639,19,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
639,20,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
639,21,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
639,22,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
639,23,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
639,24,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
639,25,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
639,26,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
639,27,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
639,28,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
639,29,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
640,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
640,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
640,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
641,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
641,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
641,3,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
641,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
642,1,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
642,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
643,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
643,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
644,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
644,2,Gastrectomy,Gastric therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
644,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
644,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
644,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
644,6,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
644,7,Therapy responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
645,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
645,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
646,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
646,2,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
646,3,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
646,4,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
646,5,Atrioventricular block first degree,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
646,6,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
646,7,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
646,8,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
646,9,Hepatic mass,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
646,10,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
646,11,Lip dry,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
646,12,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
646,13,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
646,14,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
646,15,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
646,16,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
646,17,Ventricular extrasystoles,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
647,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
647,2,Gastrointestinal tube insertion,Gastrointestinal therapeutic procedures NEC,Gastrointestinal therapeutic procedures,Surg,N
648,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
648,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
649,1,Bladder transitional cell carcinoma,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
650,1,Bundle branch block left,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
650,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
650,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
650,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
650,5,QRS axis abnormal,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
650,6,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
651,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
651,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
651,3,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
652,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
652,2,Alcohol interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
652,3,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
652,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
652,5,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
653,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
654,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
655,1,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
655,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
656,1,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
657,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
658,1,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
658,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
659,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
659,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
660,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
660,2,Inflammatory bowel disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
661,1,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
662,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
662,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
662,3,Intra-abdominal fluid collection,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
662,4,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
662,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
662,6,Monocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
662,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
662,8,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
662,9,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
662,10,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
662,11,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
663,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
663,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
663,3,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
663,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
664,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
665,1,Abdominal mass,Abdominal findings abnormal,Gastrointestinal signs and symptoms,Gastr,N
665,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
665,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
665,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
665,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
665,6,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
666,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
666,2,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
666,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
666,4,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
666,5,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
666,6,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
666,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
666,8,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
666,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
666,10,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
667,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
668,1,Accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
668,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
668,3,Blood pressure fluctuation,Blood pressure disorders NEC,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
668,4,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
668,5,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
668,6,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
668,7,Foreign body in throat,Chest and respiratory tract injuries NEC,Injuries NEC,Inj&P,N
668,8,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
669,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
669,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
669,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
669,4,Gene mutation identification test positive,Gene analyses,Cytogenetic investigations and genetic analyses,Inv,N
669,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
669,6,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
669,7,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
670,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
670,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
670,3,Panic attack,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
670,4,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
671,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
671,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
671,3,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
671,4,Skin erosion,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
671,5,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
672,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
672,2,Bronchopulmonary disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
672,3,Cardiac failure,Heart failures NEC,Heart failures,Card,N
672,4,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
672,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
672,6,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
672,7,Transplant rejection,Transplant rejections,Immune disorders NEC,Immun,N
673,1,Cervix haemorrhage uterine,Cervix disorders NEC,Cervix disorders (excl infections and inflammations),Repro,N
673,2,Menstruation irregular,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
674,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
674,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
675,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
675,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
675,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
676,1,Deafness,Hearing losses,Hearing disorders,Ear,N
677,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
677,2,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
677,3,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
677,4,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
678,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
678,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
678,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
679,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
679,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
679,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
679,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
679,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
680,1,Acute interstitial pneumonitis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
680,2,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
680,3,Right ventricular failure,Right ventricular failures,Heart failures,Card,N
681,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
681,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
681,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
681,4,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
681,5,Sputum discoloured,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
681,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
681,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
682,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
682,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
682,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
682,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
682,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
682,6,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
683,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
683,2,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
683,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
683,4,Peripheral sensorimotor neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
684,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
685,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
685,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
686,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
686,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
686,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
687,1,Eyelid oedema,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
688,1,Hydrocele,Male reproductive tract disorders congenital,Reproductive tract and breast disorders congenital,Cong,N
688,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
689,1,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
689,2,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
689,3,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
689,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
689,5,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
690,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
690,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
690,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
690,4,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
690,5,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
691,1,Bone marrow transplant,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
692,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
692,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
692,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
692,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
692,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
692,6,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
692,7,Viral cardiomyopathy,Viral infections NEC,Viral infectious disorders,Infec,N
693,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
693,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
693,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
694,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
694,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
694,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
695,1,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
696,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
696,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
696,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
696,4,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
697,1,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
697,2,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
697,3,Loss of libido,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
697,4,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
697,5,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
698,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
698,2,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
699,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
700,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
700,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
700,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
700,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
700,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
700,6,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
700,7,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
701,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
701,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
701,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
702,1,Acne,Acnes,Skin appendage conditions,Skin,N
702,2,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
702,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
702,4,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
702,5,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
702,6,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
702,7,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
702,8,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
702,9,Oral discomfort,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
702,10,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
703,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
703,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
703,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
704,1,Erythema annulare,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
705,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
706,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
707,1,Colon cancer,Colorectal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
707,2,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
707,3,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
708,1,Blast cell crisis,Leukaemias acute NEC,Leukaemias,Neopl,Y
709,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
709,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
709,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
709,4,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
710,1,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
710,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
711,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
711,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
711,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
711,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
712,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
713,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
713,2,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
713,3,Exfoliative rash,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
713,4,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
713,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
714,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
714,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
715,1,Deafness,Hearing losses,Hearing disorders,Ear,N
716,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
716,2,Pyloric stenosis,Gastric disorders congenital,Gastrointestinal tract disorders congenital,Cong,N
717,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
717,2,Exercise tolerance decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
717,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
717,4,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
717,5,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
718,1,Hyperaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
718,2,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
718,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
719,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
719,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
719,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
719,4,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
720,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
721,1,Exfoliative rash,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
721,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
722,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
722,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
722,3,Metastases to skin,Metastases to specified sites,Metastases,Neopl,N
722,4,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
722,5,Neoplasm recurrence,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
722,6,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
722,7,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
722,8,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
722,9,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
722,10,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
723,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
723,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
724,1,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
725,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
725,2,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
725,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
725,4,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
726,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
726,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
727,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
728,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
728,2,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
728,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
728,4,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
728,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
729,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
730,1,Gene mutation identification test positive,Gene analyses,Cytogenetic investigations and genetic analyses,Inv,N
730,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
731,1,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
731,2,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
732,1,Blast cell crisis,Leukaemias acute NEC,Leukaemias,Neopl,N
732,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
732,3,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
733,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
734,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
734,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
734,3,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
734,4,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
735,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
735,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
735,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
736,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
737,1,Dermatitis psoriasiform,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
737,2,Eye oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
737,3,Impaired driving ability,Disability issues,Lifestyle issues,SocCi,N
737,4,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
737,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
738,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
738,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
738,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
738,4,Tumour haemorrhage,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
739,1,Agranulocytosis,Neutropenias,White blood cell disorders,Blood,N
740,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
741,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
742,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
743,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
744,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
745,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
745,2,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
745,3,Red blood cell count increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
745,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
746,1,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
746,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
747,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
747,2,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
747,3,Epidermolysis bullosa,Skin and subcutaneous tissue disorders congenital NEC,Skin and subcutaneous tissue disorders congenital,Cong,N
747,4,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
747,5,Pemphigoid,Bullous conditions,Epidermal and dermal conditions,Skin,N
747,6,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
747,7,Pseudoporphyria,Bullous conditions,Epidermal and dermal conditions,Skin,N
748,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
748,2,Intentional self-injury,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
749,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
750,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
750,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
750,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
750,4,Therapeutic product effect prolonged,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
751,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
751,2,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
751,3,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
751,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
751,5,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
751,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
751,7,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
751,8,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
751,9,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
752,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
752,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
752,3,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
752,4,Raynaud's phenomenon,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
752,5,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
753,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
754,1,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
754,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
755,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
755,2,White coat hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
756,1,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
757,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
757,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
757,3,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
758,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
759,1,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
760,1,Hepatitis acute,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
760,2,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
760,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
761,1,Inflammatory bowel disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
762,1,Glomerulosclerosis,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
762,2,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
763,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
763,2,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
763,3,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
763,4,Myalgia,Muscle pains,Muscle disorders,Musc,N
763,5,Myopathy,Myopathies,Muscle disorders,Musc,N
763,6,Peroneal nerve palsy,Mononeuropathies,Peripheral neuropathies,Nerv,N
764,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
764,2,Cerebral ischaemia,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
764,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
765,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
766,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
766,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
767,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
767,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
768,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
768,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
769,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
769,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
770,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
770,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
771,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
771,2,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
771,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
772,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
772,2,Metastases to abdominal cavity,Metastases to specified sites,Metastases,Neopl,N
772,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
773,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
773,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
773,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
774,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
774,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
774,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
775,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
775,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
775,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
776,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
776,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
776,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
777,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
777,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
777,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
778,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
778,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
778,3,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
778,4,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
779,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
779,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
779,3,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
779,4,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
780,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
780,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
780,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
781,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
781,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
781,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
782,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
782,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
782,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
783,1,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
784,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
784,2,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
784,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
785,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
785,2,Metastases to thorax,Metastases to specified sites,Metastases,Neopl,N
785,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
786,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
786,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
787,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
787,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
787,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
788,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
788,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
789,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
789,2,Metastases to abdominal cavity,Metastases to specified sites,Metastases,Neopl,N
789,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
790,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
790,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
790,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
791,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
791,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
791,3,Intestinal metastasis,Metastases to specified sites,Metastases,Neopl,N
791,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
791,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
791,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
791,7,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
791,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
792,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
792,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
792,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
793,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
793,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
794,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
794,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
795,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
795,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
795,3,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
795,4,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
796,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
796,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
796,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
797,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
797,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
797,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
797,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
798,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
798,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
799,1,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
799,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
800,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
800,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
800,3,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
800,4,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
801,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
801,2,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
801,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
802,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
802,2,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
802,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
803,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
803,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
804,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
804,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
804,3,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
804,4,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
805,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
805,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
805,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
806,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
806,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
806,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
807,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
807,2,Metastases to bladder,Metastases to specified sites,Metastases,Neopl,N
807,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
808,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
808,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
809,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
809,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
810,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
810,2,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
810,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
811,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
811,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
811,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
812,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
812,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
813,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
813,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
814,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
814,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
814,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
815,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
815,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
816,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
816,2,Metastases to kidney,Metastases to specified sites,Metastases,Neopl,N
816,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
817,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
817,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
817,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
818,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
818,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
818,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
819,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
819,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
820,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
820,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
821,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
821,2,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
821,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
822,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
822,2,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
822,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
823,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
823,2,Metastases to pelvis,Metastases to specified sites,Metastases,Neopl,N
823,3,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
823,4,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
824,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
824,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
825,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
825,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
826,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
826,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
827,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
827,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
828,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
828,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
829,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
829,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
830,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
830,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
831,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
831,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
832,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
832,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
833,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
833,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
834,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
834,2,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
835,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
835,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
835,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
835,4,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
836,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
836,2,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
836,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
836,4,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
836,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
836,6,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
836,7,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
836,8,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
836,9,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
836,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
837,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
837,2,Hepatic enzyme abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
838,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
838,2,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
838,3,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
838,4,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
838,5,Pleural thickening,Pleural conditions NEC,Pleural disorders,Resp,N
839,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
839,2,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
839,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
840,1,Uveitis,"Iris and uveal tract infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
841,1,Ileus paralytic,Non-mechanical ileus,Gastrointestinal motility and defaecation conditions,Gastr,N
842,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
842,2,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
843,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
843,2,Intervertebral disc protrusion,Intervertebral disc disorders NEC,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
843,3,Nerve compression,Mononeuropathies,Peripheral neuropathies,Nerv,N
843,4,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
844,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
844,2,Blood uric acid increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
844,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
845,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
846,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
846,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
846,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
846,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
846,5,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
846,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
847,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
848,1,Hepatocellular carcinoma,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
848,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
849,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
849,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
849,3,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
849,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
849,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
849,6,Respiratory tract infection,Infections NEC,Infections - pathogen unspecified,Infec,N
849,7,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
850,1,Lung adenocarcinoma,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
850,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
851,1,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
852,1,CSF protein increased,Cerebrospinal fluid tests (excl microbiology),"Neurological, special senses and psychiatric investigations",Inv,N
852,2,Deafness bilateral,Hearing losses,Hearing disorders,Ear,N
852,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
852,4,Headache,Headaches NEC,Headaches,Nerv,N
852,5,Magnetic resonance imaging head abnormal,Central nervous system imaging procedures,"Neurological, special senses and psychiatric investigations",Inv,N
853,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
853,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
854,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
854,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
854,3,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
854,4,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
854,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
854,6,Hepatic enzyme abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
854,7,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
854,8,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
854,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
854,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
855,1,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
856,1,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
857,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
858,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
858,2,Graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
858,3,Parainfluenzae virus infection,Parainfluenzae viral infections,Viral infectious disorders,Infec,Y
858,4,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
859,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
859,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
859,3,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
860,1,Tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
861,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
861,2,Gastrointestinal necrosis,Gastrointestinal necrosis and gangrene (excl gangrenous hernia),Gastrointestinal vascular conditions,Gastr,N
862,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
862,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
863,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
863,2,Pulmonary congestion,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
864,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
864,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
864,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
864,4,Dyspnoea paroxysmal nocturnal,Breathing abnormalities,Respiratory disorders NEC,Resp,N
864,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
864,6,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
864,7,Orthopnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
864,8,Pulmonary congestion,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
864,9,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
865,1,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
865,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
866,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
867,1,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
867,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
867,3,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
868,1,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
868,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
869,1,Chronic myeloid leukaemia transformation,Leukaemias chronic myeloid,Leukaemias,Neopl,N
869,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
870,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
870,2,Clostridium difficile infection,Clostridia infections,Bacterial infectious disorders,Infec,N
870,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
870,4,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
870,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
870,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
871,1,Focal nodular hyperplasia,Hepatobiliary neoplasms benign,Hepatic and biliary neoplasms benign,Neopl,N
872,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
873,1,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
874,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
875,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
876,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
877,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
878,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
878,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
879,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
879,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
880,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
880,2,Chronic myeloid leukaemia transformation,Leukaemias chronic myeloid,Leukaemias,Neopl,N
880,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
881,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
881,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
881,3,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
882,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
883,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
884,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
884,2,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
884,3,Rib fracture,Thoracic cage fractures and dislocations,Bone and joint injuries,Inj&P,N
884,4,Vitamin D decreased,Vitamin analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
885,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
886,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
886,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
887,1,Papilloedema,Optic disc abnormalities NEC,"Ocular structural change, deposit and degeneration NEC",Eye,N
887,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
887,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
888,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
889,1,Clostridium difficile colitis,Clostridia infections,Bacterial infectious disorders,Infec,N
889,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
890,1,Renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
890,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
891,1,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
892,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
892,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
893,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
893,2,Peripheral motor neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
893,3,Peripheral sensory neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
894,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
894,2,Glomerulonephritis,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
894,3,Headache,Headaches NEC,Headaches,Nerv,N
894,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
894,5,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
894,6,Renal vasculitis,Renal vascular and ischaemic conditions,Renal disorders (excl nephropathies),Renal,N
895,1,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
896,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
897,1,Echinococciasis,Cestode infections,Helminthic disorders,Infec,N
897,2,Hepatic cyst,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
898,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
898,2,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
899,1,Myelocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
900,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
900,2,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
900,3,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
900,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
901,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
902,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
903,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
904,1,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
904,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
905,1,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
906,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
906,2,Pyoderma gangrenosum,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
907,1,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
908,1,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
909,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
910,1,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
911,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
911,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
911,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
911,4,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
912,1,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
913,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
913,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
913,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
913,4,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
914,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
915,1,Metastasis,Metastases to unknown and unspecified sites,Metastases,Neopl,N
915,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
916,1,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
916,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
916,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
917,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
917,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
917,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
918,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
918,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
918,3,Rash morbilliform,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
919,1,Candida infection,Candida infections,Fungal infectious disorders,Infec,N
919,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
919,3,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
919,4,Ear disorder,Ear disorders NEC,Aural disorders NEC,Ear,N
919,5,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
919,6,Inflammation,Inflammations,General system disorders NEC,Genrl,N
919,7,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
919,8,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
919,9,Mastoiditis,Ear infections,Infections - pathogen unspecified,Infec,N
919,10,Nail discolouration,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
919,11,Onychoclasis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
919,12,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
919,13,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
920,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
920,2,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
920,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
920,4,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
920,5,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
920,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
920,7,Yellow skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
921,1,Bundle branch block right,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
921,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
921,3,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
921,4,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
921,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
921,6,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
921,7,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
922,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
923,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
923,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
924,1,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
924,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
924,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
924,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
924,5,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
924,6,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
925,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
925,2,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
925,3,Chronic myeloid leukaemia transformation,Leukaemias chronic myeloid,Leukaemias,Neopl,N
925,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
925,5,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
925,6,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
926,1,Dermatitis exfoliative generalised,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
926,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
926,3,Toxic skin eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
927,1,Metastases to liver,Metastases to specified sites,Metastases,Neopl,Y
927,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
927,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
928,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
929,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
929,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
929,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
929,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
930,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
930,2,Hypotrichosis,Alopecias,Skin appendage conditions,Skin,N
930,3,Skin hypopigmentation,Hypopigmentation disorders,Pigmentation disorders,Skin,N
931,1,Gastrointestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
931,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
932,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
933,1,Mycobacterial infection,Atypical mycobacterial infections,Mycobacterial infectious disorders,Infec,N
934,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
934,2,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
934,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
935,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
935,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
936,1,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
937,1,Deafness neurosensory,Hearing losses,Hearing disorders,Ear,N
938,1,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
939,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
939,2,Myocarditis,Noninfectious myocarditis,Myocardial disorders,Card,N
939,3,Troponin increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
940,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
940,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
940,3,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
940,4,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
940,5,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
940,6,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
940,7,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
940,8,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
940,9,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
940,10,Hypomania,Mood alterations with manic symptoms,Manic and bipolar mood disorders and disturbances,Psych,N
940,11,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
940,12,Mental impairment,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
940,13,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
940,14,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
940,15,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
940,16,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
940,17,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
940,18,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
940,19,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
941,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
941,2,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
941,3,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
942,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
943,1,Bowel movement irregularity,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
943,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
943,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
944,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
944,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
944,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
944,4,Ear discomfort,Ear disorders NEC,Aural disorders NEC,Ear,N
944,5,Eustachian tube obstruction,Eustachian tube disorders,Middle ear disorders (excl congenital),Ear,N
944,6,Increased bronchial secretion,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
944,7,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
944,8,Onycholysis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
944,9,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
945,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
945,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
945,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
945,4,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
945,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
945,6,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
945,7,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
945,8,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
945,9,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
945,10,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
946,1,Acute generalised exanthematous pustulosis,Pustular conditions,Epidermal and dermal conditions,Skin,N
946,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
946,3,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
946,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
946,5,Pustule,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
946,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
946,7,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
946,8,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
947,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
948,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
948,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
949,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
949,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
950,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
950,2,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
950,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
951,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
951,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
952,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
952,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
953,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
953,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
954,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
954,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
955,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
955,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
956,1,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
956,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
956,3,Post procedural complication,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
957,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
957,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
958,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
958,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
959,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
959,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
960,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
960,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
961,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
961,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
962,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
962,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
963,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
963,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
964,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
965,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
965,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
966,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
966,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
967,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
967,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
968,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
968,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
969,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
969,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
970,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
970,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
971,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
971,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
972,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
972,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
973,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
973,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
974,1,Adenoid cystic carcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
974,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
975,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
975,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
976,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
976,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
976,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
977,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
977,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
977,3,Metastatic neoplasm,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
978,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
978,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
979,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
979,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
980,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
980,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
980,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
980,4,Musculoskeletal pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
980,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
980,6,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
980,7,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
980,8,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
981,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
981,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
982,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
982,2,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
982,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
983,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
983,2,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
983,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
983,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
984,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
985,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
986,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
986,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
987,1,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
987,2,Immune system disorder,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
987,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
987,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
988,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
988,2,Metastases to meninges,Metastases to specified sites,Metastases,Neopl,N
988,3,Myeloid leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
989,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
989,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
990,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
990,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
990,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
991,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
991,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
992,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
992,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
992,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
992,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
993,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
994,1,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
994,2,Iridocyclitis,"Iris and uveal tract infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
994,3,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
995,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
996,1,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
996,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
996,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
996,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
997,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,Y
998,1,Blast cell crisis,Leukaemias acute NEC,Leukaemias,Neopl,N
998,2,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,Y
998,3,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
999,1,Astrocytoma,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,Y
999,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
999,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
999,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1000,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1000,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1001,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1002,1,Blood thyroid stimulating hormone increased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
1003,1,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1004,1,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1005,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1005,2,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1005,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1005,4,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1005,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1006,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1006,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1006,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1007,1,Chronic graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1007,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1008,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1008,2,Pneumonia cytomegaloviral,Cytomegaloviral infections,Viral infectious disorders,Infec,N
1008,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1009,1,Acute graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1009,2,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1009,3,Chronic graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1009,4,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1009,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1009,6,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
1009,7,Transplant rejection,Transplant rejections,Immune disorders NEC,Immun,N
1010,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1010,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1010,3,Post transplant lymphoproliferative disorder,Lymphoproliferative disorders NEC (excl leukaemias and lymphomas),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
1011,1,Chronic graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1011,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1011,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1012,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,Y
1012,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1013,1,Acute graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1013,2,Chronic graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1013,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1013,4,Post transplant lymphoproliferative disorder,Lymphoproliferative disorders NEC (excl leukaemias and lymphomas),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
1014,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1014,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1015,1,Ankle fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1016,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
1016,2,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1017,1,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
1018,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1019,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1020,1,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1021,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1022,1,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1022,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1023,1,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1023,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1024,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1025,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
1025,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1025,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1025,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1025,5,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
1025,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1026,1,Intervertebral disc disorder,Intervertebral disc disorders NEC,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
1027,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1028,1,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
1029,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1029,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1029,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1029,4,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
1029,5,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1030,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1030,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1030,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1031,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1031,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1032,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1032,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1032,3,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1033,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1033,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1033,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
1033,4,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1034,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1034,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1034,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
1034,4,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1035,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1035,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
1035,3,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1035,4,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
1035,5,Thyroid cancer,Thyroid neoplasms malignant,Endocrine neoplasms malignant and unspecified,Neopl,N
1036,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1036,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1036,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1036,4,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1036,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1036,6,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
1037,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
1037,2,Atrioventricular block,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
1037,3,Atrioventricular block complete,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
1037,4,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1038,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1039,1,Inappropriate antidiuretic hormone secretion,Posterior pituitary disorders,Hypothalamus and pituitary gland disorders,Endo,N
1040,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
1040,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1041,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1042,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1042,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1043,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
1043,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1043,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1043,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1044,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1044,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1044,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1045,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1046,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1046,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1046,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1046,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1046,5,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1046,6,Spinal compression fracture,Spinal fractures and dislocations,Bone and joint injuries,Inj&P,N
1047,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1047,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1047,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1048,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1048,2,Lupus-like syndrome,Lupus erythematosus (incl subtypes),Connective tissue disorders (excl congenital),Musc,N
1049,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1050,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1050,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1050,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1051,1,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,Y
1051,2,Plasmacytoma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
1051,3,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1052,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1052,2,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,Y
1052,3,Chronic myeloid leukaemia transformation,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1053,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1053,2,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1053,3,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1053,4,Coronary artery stenosis,Coronary artery disorders NEC,Coronary artery disorders,Card,N
1053,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1053,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1053,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1054,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
1055,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1056,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
1056,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1056,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1057,1,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1058,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1058,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
1058,3,Gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
1058,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1058,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1059,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1059,2,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
1060,1,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
1060,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1060,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1061,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1061,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1062,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1062,2,Breakthrough pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1062,3,Cholecystitis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
1062,4,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1062,5,Food intolerance,Food malabsorption and intolerance syndromes (excl sugar intolerance),Food intolerance syndromes,Metab,N
1062,6,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1062,7,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1063,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1064,1,Superficial spreading melanoma stage I,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,N
1065,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1065,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1066,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1067,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1067,2,Blood pressure systolic increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
1067,3,Cardiotoxicity,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1067,4,Crepitations,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1067,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1067,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1067,7,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1067,8,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1067,9,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1067,10,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
1067,11,Hepatosplenomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
1067,12,Hordeolum,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
1067,13,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1067,14,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1067,15,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1067,16,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1067,17,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
1067,18,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1067,19,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1067,20,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1067,21,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
1067,22,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
1067,23,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1067,24,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1067,25,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1068,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1068,2,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
1068,3,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
1068,4,Cryoglobulinaemia,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
1068,5,Glomerulonephritis,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
1068,6,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1068,7,Leukocyturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1068,8,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
1068,9,Protein total,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
1068,10,Renal vein thrombosis,Renal vascular and ischaemic conditions,Renal disorders (excl nephropathies),Renal,N
1068,11,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1069,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1069,2,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1069,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1069,4,Perthes disease,Epiphyseal disorders,Bone disorders (excl congenital and fractures),Musc,N
1070,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1070,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1070,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1070,4,Early satiety,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1070,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1070,6,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1070,7,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
1070,8,Systemic mastocytosis,Haematologic neoplasms NEC,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
1071,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
1071,2,Chronic myeloid leukaemia transformation,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1072,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1073,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1073,2,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1073,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1073,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1074,1,Bladder adenocarcinoma stage unspecified,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1075,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1076,1,Malignant melanoma,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,N
1076,2,Spinal cord compression,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
1077,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1077,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1077,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
1077,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1077,5,Peripheral arterial occlusive disease,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1077,6,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1077,7,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1077,8,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1078,1,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1079,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1080,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1080,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1080,3,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
1080,4,Vascular stenosis,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1081,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1081,2,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
1081,3,Ejection fraction decreased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1082,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1082,2,Cardiogenic shock,Heart failures NEC,Heart failures,Card,N
1082,3,Dilated cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
1083,1,Orbital oedema,"Orbital structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
1083,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1083,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1084,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1084,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1084,3,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1084,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1084,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1084,6,Headache,Headaches NEC,Headaches,Nerv,N
1084,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1084,8,Malnutrition,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
1084,9,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1084,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1085,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1085,2,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
1085,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1085,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1086,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
1086,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1086,3,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1086,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1086,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1086,6,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1087,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1087,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1088,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1088,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1088,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
1089,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1089,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1089,3,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1089,4,Tubulointerstitial nephritis,Nephritis NEC,Nephropathies,Renal,N
1089,5,Urate nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
1090,1,Angiomyolipoma,Soft tissue neoplasms benign NEC,Soft tissue neoplasms benign,Neopl,N
1090,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1090,3,Tuberous sclerosis complex,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
1091,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1092,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1093,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1093,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1094,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1094,2,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1094,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1094,4,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1094,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1094,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1094,7,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
1094,8,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1095,1,Philadelphia chromosome positive,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1096,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1096,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1096,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1096,4,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1096,5,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
1096,6,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1097,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
1097,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1097,3,Blood phosphorus decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
1097,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1098,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1099,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1099,2,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
1099,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1099,4,Hypertensive encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
1099,5,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
1099,6,Posterior reversible encephalopathy syndrome,Encephalopathies NEC,Encephalopathies,Nerv,N
1099,7,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1099,8,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1100,1,Arthritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
1101,1,"Bladder cancer stage 0, with cancer in situ",Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1102,1,Chordoma,Bone neoplasms unspecified malignancy,Skeletal neoplasms malignant and unspecified,Neopl,N
1102,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1102,3,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
1102,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1103,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1104,1,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
1104,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1105,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1105,2,Encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
1105,3,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1106,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
1106,2,Graft versus host disease in lung,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1106,3,Graft versus host disease in skin,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1106,4,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
1107,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1108,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1109,1,Demyelination,Demyelinating disorders NEC,Demyelinating disorders,Nerv,N
1109,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1110,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1110,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1110,3,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
1111,1,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1112,1,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
1113,1,Malignant melanoma,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,N
1113,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1113,3,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
1113,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1114,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
1115,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
1115,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1115,3,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1116,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1116,2,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1116,3,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
1116,4,Philadelphia chromosome positive,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1116,5,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1117,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1118,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1119,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1119,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
1120,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1120,2,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1121,1,Demyelination,Demyelinating disorders NEC,Demyelinating disorders,Nerv,N
1121,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1121,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1121,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1122,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1122,2,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1122,3,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1122,4,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1123,1,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
1123,2,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
1123,3,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1124,1,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1124,2,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1125,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1125,2,Shoulder fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1126,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
1126,2,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1127,1,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
1128,1,Conjunctival oedema,"Conjunctival infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
1128,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1128,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1129,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1130,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1130,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1130,3,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
1130,4,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
1130,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1130,6,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
1131,1,Immunodeficiency,Immunodeficiency disorders NEC,Immunodeficiency syndromes,Immun,N
1131,2,Infected skin ulcer,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
1131,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1131,4,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
1131,5,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
1132,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
1132,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1133,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
1133,2,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
1133,3,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
1134,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1134,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1134,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1135,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1135,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1136,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1136,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1136,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1137,1,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
1137,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1138,1,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1139,1,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
1140,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1141,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1141,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1142,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1143,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
1144,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1144,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
1144,3,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
1145,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1145,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1146,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
1146,2,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1146,3,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1147,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1147,2,Eye pruritus,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
1147,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1147,4,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1147,5,Pruritus genital,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
1147,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1148,1,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1148,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1148,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1148,4,Scleroderma-like reaction,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
1149,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1149,2,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1150,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1150,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1150,3,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1151,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1151,2,Gastrointestinal tract irritation,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
1151,3,Irritable bowel syndrome,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
1152,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
1152,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1153,1,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
1153,2,Lactation disorder,Lactation disorders,Breast disorders,Repro,N
1154,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
1155,1,Chronic graft versus host disease in skin,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1155,2,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
1155,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1155,4,Skin hyperpigmentation,Hyperpigmentation disorders,Pigmentation disorders,Skin,N
1155,5,Skin hypopigmentation,Hypopigmentation disorders,Pigmentation disorders,Skin,N
1156,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1156,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
1156,3,Blood creatinine decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
1156,4,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
1156,5,Chronic graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1156,6,Concomitant disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1156,7,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
1156,8,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1156,9,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1157,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1158,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1159,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1160,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1161,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1162,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1163,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1164,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1165,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1166,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1167,1,Malignant melanoma,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,N
1167,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1168,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1169,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1169,2,Benign neoplasm,Neoplasms benign site unspecified NEC,Miscellaneous and site unspecified neoplasms benign,Neopl,N
1169,3,Brain neoplasm,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
1169,4,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1169,5,Meningioma,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
1169,6,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1169,7,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1169,8,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1169,9,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1169,10,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1170,1,Abnormal faeces,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1170,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1170,3,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
1171,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1171,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1171,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1172,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1173,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1173,2,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1173,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1173,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1174,1,Clavicle fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1175,1,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1175,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1176,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1176,2,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
1176,3,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
1176,4,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
1176,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1177,1,Chronic graft versus host disease in skin,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1177,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1177,3,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
1177,4,Skin tightness,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1178,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1178,2,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
1178,3,Gastric perforation,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1178,4,Gastrointestinal inflammation,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
1178,5,Gastrointestinal wall thickening,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1179,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1180,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1181,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1181,2,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
1181,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1182,1,Bronchiectasis,Bronchial conditions NEC,Bronchial disorders (excl neoplasms),Resp,N
1182,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1182,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1182,4,Pleural thickening,Pleural conditions NEC,Pleural disorders,Resp,N
1182,5,Pulmonary congestion,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1183,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1183,2,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
1183,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
1183,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1184,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1184,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1184,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1184,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1184,5,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1185,1,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1185,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1186,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1186,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1186,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1186,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1186,5,Peripheral sensory neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
1186,6,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1187,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1187,2,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1187,3,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1188,1,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
1188,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
1189,1,Left ventricular failure,Left ventricular failures,Heart failures,Card,N
1190,1,Follicular lymphoma,Follicular lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
1190,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1191,1,Onychoclasis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
1191,2,Onychomadesis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
1191,3,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1192,1,Bronchiectasis,Bronchial conditions NEC,Bronchial disorders (excl neoplasms),Resp,N
1192,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1192,3,Parainfluenzae virus infection,Parainfluenzae viral infections,Viral infectious disorders,Infec,N
1192,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1192,5,Pulmonary function test decreased,Respiratory and pulmonary function diagnostic procedures,Respiratory and pulmonary investigations (excl blood gases),Inv,N
1193,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1194,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1194,2,Pyoderma gangrenosum,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
1194,3,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
1194,4,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1194,5,Skin plaque,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1194,6,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
1195,1,Alopecia scarring,Alopecias,Skin appendage conditions,Skin,N
1195,2,Graft versus host disease in skin,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1196,1,Chest expansion decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1196,2,Forced expiratory volume decreased,Respiratory and pulmonary function diagnostic procedures,Respiratory and pulmonary investigations (excl blood gases),Inv,N
1196,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1196,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1197,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1197,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1198,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1198,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1198,3,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1199,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1199,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1199,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1199,4,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1200,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1200,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1201,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1201,2,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
1202,1,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1202,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1203,1,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
1203,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1203,3,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
1203,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1203,5,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1203,6,Transaminases increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1203,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1204,1,Concomitant disease aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1204,2,Forced expiratory volume decreased,Respiratory and pulmonary function diagnostic procedures,Respiratory and pulmonary investigations (excl blood gases),Inv,N
1204,3,Graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1204,4,Hypokinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
1204,5,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1204,6,Scleroderma,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
1204,7,Skin abrasion,Skin injuries NEC,Injuries NEC,Inj&P,N
1204,8,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1205,1,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1206,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1207,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1208,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1209,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1209,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1210,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
1211,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
1211,2,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,Y
1212,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
1212,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1213,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
1214,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1214,2,Blood iron decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
1214,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1214,4,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1214,5,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1214,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1215,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1215,2,Advanced systemic mastocytosis,Haematologic neoplasms NEC,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
1215,3,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1215,4,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
1215,5,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1215,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1215,7,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1215,8,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
1215,9,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1216,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
1216,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1216,3,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1216,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1216,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1216,6,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
1216,7,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1217,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1217,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
1218,1,Oral pigmentation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1219,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1220,1,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
1221,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1222,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1223,1,Oropharyngeal cancer,"Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified",Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,Y
1223,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1224,1,Dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1224,2,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1225,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1225,2,Dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1225,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1225,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1225,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1225,6,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
1225,7,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1226,1,Oropharyngeal cancer,"Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified",Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,Y
1226,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1227,1,Dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1227,2,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
1227,3,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1228,1,Ovarian cancer,Ovarian neoplasms malignant (excl germ cell),Reproductive neoplasms female malignant and unspecified,Neopl,N
1228,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1229,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1229,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1230,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1230,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1230,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1231,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1231,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1232,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1232,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1233,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1233,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1234,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
1234,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1235,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1235,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1236,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1236,2,Gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
1236,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1237,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1237,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1237,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1238,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1239,1,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
1240,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1241,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1242,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
1243,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1243,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1243,3,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1243,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1244,1,Feeling jittery,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1244,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1245,1,Activated partial thromboplastin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1245,2,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
1245,3,Ammonia increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1245,4,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1245,5,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1245,6,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
1245,7,Blood fibrinogen decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1245,8,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
1245,9,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
1245,10,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1245,11,Death,Death and sudden death,Fatal outcomes,Genrl,N
1245,12,Fibrin D dimer increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1245,13,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1245,14,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1245,15,Hepatic encephalopathy,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
1245,16,Hepatic necrosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1245,17,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1245,18,Intracranial pressure increased,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
1245,19,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1245,20,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1245,21,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
1245,22,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1245,23,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1245,24,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1245,25,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1246,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1246,2,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
1246,3,Depression suicidal,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1246,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1246,5,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1246,6,Reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1246,7,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
1247,1,Gastric cancer,Gastric neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1247,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1248,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1248,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1249,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
1249,2,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
1249,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1249,4,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1249,5,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1249,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1249,7,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1249,8,Headache,Headaches NEC,Headaches,Nerv,N
1249,9,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1249,10,Myalgia,Muscle pains,Muscle disorders,Musc,N
1249,11,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1249,12,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
1249,13,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
1249,14,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
1249,15,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1249,16,Type 1 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1250,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
1251,1,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1251,2,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1252,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1252,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1252,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1253,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1253,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1254,1,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1254,2,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1255,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1256,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1256,2,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1256,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1256,4,Hypervolaemia,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1256,5,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
1256,6,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1256,7,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1256,8,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1256,9,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1257,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1258,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
1258,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1258,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1258,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1258,5,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
1258,6,Uveitis,"Iris and uveal tract infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
1259,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1259,2,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1260,1,Philadelphia chromosome positive,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1260,2,Polymerase chain reaction,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1261,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1261,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
1261,3,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1261,4,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
1261,5,Ehlers-Danlos syndrome,Connective tissue disorders congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
1261,6,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
1261,7,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1261,8,Ventricular tachycardia,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
1262,1,Product after taste,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1262,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1263,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1263,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1263,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1263,4,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
1263,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1263,6,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1263,7,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
1263,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1263,9,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1263,10,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1263,11,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1263,12,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
1263,13,Tonsillar ulcer,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
1264,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
1264,2,Pseudoporphyria,Bullous conditions,Epidermal and dermal conditions,Skin,N
1265,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1265,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1265,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1265,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1266,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1266,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1266,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1267,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
1267,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
1267,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1268,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1269,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1270,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
1270,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1270,3,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1270,4,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
1270,5,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1270,6,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1270,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1270,8,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1271,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1271,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1271,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1271,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1272,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1272,2,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1272,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1272,4,Graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1272,5,Immunosuppression,Immunodeficiency disorders NEC,Immunodeficiency syndromes,Immun,N
1272,6,Leukaemia recurrent,Leukaemias NEC,Leukaemias,Neopl,N
1272,7,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1272,8,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1272,9,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1272,10,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1272,11,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1273,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
1273,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1273,3,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1273,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1273,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1273,6,Migraine,Migraine headaches,Headaches,Nerv,N
1273,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1273,8,Peripheral arterial occlusive disease,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1273,9,Peripheral vascular disorder,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1273,10,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1273,11,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1273,12,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
1273,13,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1273,14,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1274,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1274,2,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1275,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1275,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1276,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1276,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1277,1,Hepatocellular injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1277,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1278,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
1278,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1278,3,Hepatocellular injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1278,4,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
1278,5,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1278,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1279,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1279,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1279,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1279,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1280,1,Hepatocellular injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1280,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1281,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1281,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1281,3,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
1281,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1282,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1283,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1283,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1284,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1285,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1286,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
1286,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1286,3,Reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1287,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1287,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1288,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1288,2,Cardio-respiratory distress,Heart failures NEC,Heart failures,Card,N
1288,3,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
1288,4,Restrictive cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
1289,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
1289,2,Parainfluenzae virus infection,Parainfluenzae viral infections,Viral infectious disorders,Infec,N
1289,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1290,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1291,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1291,2,Fear,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
1292,1,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
1292,2,Bronchopulmonary aspergillosis,Aspergillus infections,Fungal infectious disorders,Infec,N
1292,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1292,4,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1292,5,Lung abscess,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1292,6,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1292,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1292,8,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1293,1,Bronchopulmonary aspergillosis,Aspergillus infections,Fungal infectious disorders,Infec,N
1293,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1293,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1293,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1294,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
1294,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1294,3,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1294,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
1295,1,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
1295,2,Bronchopulmonary aspergillosis,Aspergillus infections,Fungal infectious disorders,Infec,N
1295,3,Lung abscess,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1295,4,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1296,1,Bronchopulmonary aspergillosis,Aspergillus infections,Fungal infectious disorders,Infec,N
1296,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1296,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1296,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1296,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1297,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1297,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1297,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1298,1,Bronchopulmonary aspergillosis,Aspergillus infections,Fungal infectious disorders,Infec,N
1299,1,Bronchopulmonary aspergillosis,Aspergillus infections,Fungal infectious disorders,Infec,N
1300,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
1300,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1300,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1300,4,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1300,5,Normal newborn,Normal newborn status,"Pregnancy, labour, delivery and postpartum conditions",Preg,N
1300,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1301,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1302,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
1303,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
1304,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1304,2,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
1304,3,Gastrointestinal erosion,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
1304,4,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1304,5,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
1304,6,Transformation to acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
1305,1,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1306,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
1306,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1306,3,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1306,4,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1306,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1307,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
1307,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1307,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1308,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
1308,2,Philadelphia chromosome positive,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1308,3,Polyhydramnios,Amniotic fluid and cavity disorders of pregnancy NEC,"Placental, amniotic and cavity disorders (excl haemorrhages)",Preg,N
1308,4,Postoperative wound infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1309,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1310,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1310,2,Eosinophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1311,1,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1311,2,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
1311,3,Left ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
1312,1,Defaecation urgency,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
1312,2,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
1312,3,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1313,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1313,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1313,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1314,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1314,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1315,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1316,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1317,1,Bronchopulmonary aspergillosis,Aspergillus infections,Fungal infectious disorders,Infec,N
1318,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1319,1,Bronchopulmonary aspergillosis,Aspergillus infections,Fungal infectious disorders,Infec,N
1320,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1321,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1321,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
1321,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1321,4,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1321,5,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1321,6,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1322,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
1322,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1323,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1323,2,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1323,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1323,4,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1324,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
1325,1,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1326,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1327,1,Coronary artery stenosis,Coronary artery disorders NEC,Coronary artery disorders,Card,N
1327,2,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1327,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1327,4,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1327,5,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1327,6,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1327,7,Gene mutation identification test positive,Gene analyses,Cytogenetic investigations and genetic analyses,Inv,N
1327,8,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1327,9,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1328,1,Ischaemic hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1329,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1329,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1329,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1329,4,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1329,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1329,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1329,7,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
1330,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1331,1,Chordoma,Bone neoplasms unspecified malignancy,Skeletal neoplasms malignant and unspecified,Neopl,N
1331,2,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
1331,3,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
1331,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1331,5,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1332,1,Acute generalised exanthematous pustulosis,Pustular conditions,Epidermal and dermal conditions,Skin,N
1332,2,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
1333,1,Acute coronary syndrome,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
1333,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1333,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1333,4,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
1334,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1334,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1334,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
1334,4,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1334,5,Respiratory syncytial virus infection,Respiratory syncytial viral infections,Viral infectious disorders,Infec,N
1335,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1335,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1335,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
1335,4,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
1336,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1336,2,Escherichia infection,Escherichia infections,Bacterial infectious disorders,Infec,N
1336,3,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1336,4,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1336,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
1337,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1337,2,Escherichia infection,Escherichia infections,Bacterial infectious disorders,Infec,N
1337,3,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
1337,4,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1338,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1338,2,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,Y
1339,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1339,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
1339,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1339,4,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
1340,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1340,2,Enterococcal infection,Enterococcal infections,Bacterial infectious disorders,Infec,Y
1340,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1341,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1341,2,Product formulation issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1341,3,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1342,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1342,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
1342,3,Intestinal ischaemia,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
1342,4,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
1343,1,Concomitant disease aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1343,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1343,3,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
1344,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1344,2,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1344,3,Right ventricular diastolic collapse,Myocardial disorders NEC,Myocardial disorders,Card,N
1345,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1345,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1346,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1346,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1347,1,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1347,2,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
1348,1,Breath sounds abnormal,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1348,2,Cardiomegaly,Myocardial disorders NEC,Myocardial disorders,Card,N
1348,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1348,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1348,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1348,6,Grunting,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1348,7,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
1348,8,Normocytic anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1348,9,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1348,10,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1348,11,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1348,12,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1348,13,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1348,14,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
1348,15,Right ventricular diastolic collapse,Myocardial disorders NEC,Myocardial disorders,Card,N
1348,16,Sinus tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
1348,17,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1348,18,Tachypnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1348,19,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1349,1,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1349,2,Right ventricular diastolic collapse,Myocardial disorders NEC,Myocardial disorders,Card,N
1350,1,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1350,2,Right ventricular diastolic collapse,Myocardial disorders NEC,Myocardial disorders,Card,N
1351,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1351,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1351,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1351,4,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
1351,5,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1351,6,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1351,7,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1351,8,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
1351,9,Tachypnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1351,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1352,1,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1353,1,Central nervous system neoplasm,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
1353,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1353,3,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
1353,4,Pneumonia legionella,Legionella infections,Bacterial infectious disorders,Infec,N
1354,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
1355,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1355,2,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1355,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1356,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1357,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1357,2,Enterococcal infection,Enterococcal infections,Bacterial infectious disorders,Infec,N
1357,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
1357,4,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
1358,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1358,2,Gastrointestinal perforation,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
1358,3,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
1358,4,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
1359,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1359,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1359,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1359,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1359,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1359,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1360,1,Osteonecrosis of jaw,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1361,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
1361,2,Headache,Headaches NEC,Headaches,Nerv,N
1361,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1362,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1363,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1363,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1363,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1364,1,Fibroma,Neoplasms benign site unspecified NEC,Miscellaneous and site unspecified neoplasms benign,Neopl,N
1365,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1366,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1366,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1367,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1367,2,Hyperamylasaemia,Metabolic disorders NEC,Metabolism disorders NEC,Metab,N
1367,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1368,1,Skin fragility,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1368,2,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
1369,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1369,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
1369,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1370,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
1371,1,Haematotoxicity,Haematological disorders,Haematological disorders NEC,Blood,N
1371,2,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
1372,1,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1373,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1373,2,Clonal evolution,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
1373,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1374,1,Abdominal compartment syndrome,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1374,2,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1374,3,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
1374,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1375,1,Graft versus host disease in skin,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1376,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1376,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1376,3,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
1376,4,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1376,5,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1376,6,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1376,7,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1376,8,Ear pain,Ear disorders NEC,Aural disorders NEC,Ear,N
1376,9,Graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1376,10,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1376,11,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1376,12,Myalgia,Muscle pains,Muscle disorders,Musc,N
1376,13,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1376,14,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1376,15,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1376,16,Shift to the left,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1376,17,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1376,18,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1376,19,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1377,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1378,1,Blood pH increased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
1378,2,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1378,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1378,4,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1378,5,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1378,6,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
1379,1,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
1379,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1380,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1380,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
1380,3,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1381,1,Drug reaction with eosinophilia and systemic symptoms,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
1381,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1382,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1383,1,Arterial disorder,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
1383,2,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1383,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1383,4,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1383,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1383,6,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1384,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1384,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1384,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1384,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1384,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1384,6,Myalgia,Muscle pains,Muscle disorders,Musc,N
1385,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1385,2,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
1385,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1385,4,Product blister packaging issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1385,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1385,6,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1386,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1387,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1387,2,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1388,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1388,2,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1389,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1390,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1391,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1391,2,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1391,3,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1392,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1392,2,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1392,3,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1392,4,Diarrhoea haemorrhagic,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1392,5,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1393,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1394,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1394,2,Product formulation issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1395,1,Axonal neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
1395,2,Demyelination,Demyelinating disorders NEC,Demyelinating disorders,Nerv,N
1395,3,Leukoencephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,Y
1396,1,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1396,2,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1397,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
1397,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1397,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1397,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1397,5,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1397,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1397,7,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
1397,8,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
1397,9,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1397,10,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1397,11,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1398,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1399,1,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1399,2,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1399,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1400,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1400,2,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1400,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1401,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1401,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1401,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1401,4,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1401,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1401,6,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1402,1,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1403,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1403,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1403,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1403,4,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
1403,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1403,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1404,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1405,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1405,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1406,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1406,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
1406,3,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1406,4,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1406,5,Ejection fraction,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1406,6,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
1406,7,Multiple sclerosis,Multiple sclerosis acute and progressive,Demyelinating disorders,Nerv,N
1406,8,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1406,9,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
1406,10,Poor venous access,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
1406,11,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1406,12,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1406,13,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1407,1,Chronic graft versus host disease in skin,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1407,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1407,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
1407,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1408,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1408,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1409,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1410,1,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
1411,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1411,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1411,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1411,4,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
1412,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1412,2,Pyoderma gangrenosum,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
1412,3,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
1412,4,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1412,5,Skin plaque,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1412,6,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
1413,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1413,2,Polymerase chain reaction positive,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1413,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1414,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1414,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1414,3,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
1414,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1414,5,Renal artery stenosis,Renal vascular and ischaemic conditions,Renal disorders (excl nephropathies),Renal,N
1414,6,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1415,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1415,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
1415,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1415,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1415,5,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1415,6,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1416,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1416,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1416,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1416,4,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1416,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1416,6,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1416,7,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1417,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1417,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1418,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1418,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1418,3,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
1419,1,Intraductal proliferative breast lesion,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
1420,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1421,1,Clonal evolution,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
1421,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1421,3,Loss of therapeutic response,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1421,4,Peripheral vascular disorder,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1421,5,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1422,1,Clonal evolution,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
1422,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1422,3,Loss of therapeutic response,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1422,4,Peripheral vascular disorder,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1422,5,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1423,1,Melanocytic naevus,Skin neoplasms benign,Cutaneous neoplasms benign,Neopl,N
1423,2,Oral pigmentation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1424,1,Melanocytic naevus,Skin neoplasms benign,Cutaneous neoplasms benign,Neopl,N
1424,2,Oral pigmentation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1425,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1425,2,Patient dissatisfaction with treatment,Social issues NEC,Lifestyle issues,SocCi,N
1426,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1426,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1427,1,Oral pigmentation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1427,2,Skin hyperpigmentation,Hyperpigmentation disorders,Pigmentation disorders,Skin,N
1428,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1429,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
1429,2,Reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1430,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1431,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1432,1,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1433,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1434,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1435,1,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1435,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1435,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1435,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1436,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1436,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1436,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1437,1,Lipase increased,Digestive enzymes,Gastrointestinal investigations,Inv,N
1438,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1439,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1440,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1440,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1440,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1441,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1441,2,Pulmonary aplasia,Pulmonary and bronchial disorders congenital,Respiratory disorders congenital,Cong,N
1442,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1443,1,Aphthous ulcer,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
1443,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1443,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
1443,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1444,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1444,2,Crying,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1444,3,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
1444,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1444,5,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1444,6,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
1444,7,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1445,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1446,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1446,2,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1446,3,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1446,4,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1446,5,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1446,6,Graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1446,7,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1447,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1447,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1447,3,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1447,4,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1448,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1448,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1449,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1449,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1450,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1451,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1452,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1453,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1453,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1453,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1453,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1453,5,Exophthalmos,"Structural change, deposit and degeneration of eye NEC","Ocular structural change, deposit and degeneration NEC",Eye,N
1453,6,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1453,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1453,8,Periorbital swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
1453,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1454,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1455,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1456,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1457,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1457,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1458,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1459,1,Anaemia macrocytic,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1459,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1459,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1459,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1459,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1459,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1459,7,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1459,8,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
1459,9,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1460,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1461,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1461,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1462,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1462,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1462,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1462,4,Vascular insufficiency,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1463,1,Oral pigmentation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1464,1,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1465,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1465,2,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1465,3,Bone marrow disorder,Haematological disorders,Haematological disorders NEC,Blood,N
1465,4,Bone neoplasm,Bone neoplasms unspecified malignancy,Skeletal neoplasms malignant and unspecified,Neopl,N
1465,5,Central nervous system neoplasm,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
1465,6,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1465,7,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
1465,8,Loss of CAR T-cell persistence,Site specific procedural complications NEC,Procedural related injuries and complications NEC,Inj&P,N
1465,9,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1466,1,Skin hyperpigmentation,Hyperpigmentation disorders,Pigmentation disorders,Skin,N
1467,1,Cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
1467,2,Left ventricular hypertrophy,Myocardial disorders NEC,Myocardial disorders,Card,N
1467,3,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1467,4,Pulmonary arterial hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
1468,1,Oral pigmentation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1468,2,Skin hyperpigmentation,Hyperpigmentation disorders,Pigmentation disorders,Skin,N
1469,1,Oral pigmentation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1469,2,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
1470,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1470,2,Headache,Headaches NEC,Headaches,Nerv,N
1470,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
1471,1,Skin hyperpigmentation,Hyperpigmentation disorders,Pigmentation disorders,Skin,N
1472,1,Oral pigmentation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1473,1,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1473,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1474,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1475,1,Oral mucosal discolouration,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1476,1,Oral mucosal discolouration,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1477,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
1478,1,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
1479,1,Desmoid tumour,Soft tissue neoplasms benign NEC,Soft tissue neoplasms benign,Neopl,N
1480,1,Cytogenetic abnormality,Chromosomal abnormalities NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
1480,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1481,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1481,2,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1481,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1481,4,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1481,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1481,6,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1482,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1482,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1482,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1483,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1484,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1484,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1484,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1485,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1485,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1485,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1486,1,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1486,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1487,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1487,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1488,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1488,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1488,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1489,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1489,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1490,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1491,1,Melanocytic naevus,Skin neoplasms benign,Cutaneous neoplasms benign,Neopl,N
1491,2,Oral pigmentation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1492,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1492,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1493,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1494,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1495,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1495,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1495,3,Philadelphia chromosome positive,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1495,4,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1495,5,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1495,6,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1496,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1496,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1496,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1496,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1497,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1497,2,Philadelphia chromosome positive,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1498,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1498,2,Philadelphia chromosome positive,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1499,1,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1499,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1500,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1500,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1501,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1501,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1501,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1502,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1502,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1502,3,Rash pustular,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
1503,1,Polymerase chain reaction,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1504,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1504,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1504,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1504,4,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1504,5,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1504,6,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
1504,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1505,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1506,1,Ageusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
1506,2,Anosmia,Olfactory nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
1506,3,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1506,4,Headache,Headaches NEC,Headaches,Nerv,N
1506,5,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1506,6,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
1506,7,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
1506,8,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
1507,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1507,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1508,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1508,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1508,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1508,4,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1508,5,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1508,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1508,7,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1508,8,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1508,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1509,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1509,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1509,3,Skin oedema,Skin vascular conditions NEC,Skin vascular abnormalities,Skin,N
1510,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1511,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1512,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1513,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1513,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1514,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1514,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1514,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1514,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1514,5,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1515,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1515,2,Acute lymphocytic leukaemia recurrent,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1515,3,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1515,4,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1515,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1515,6,Duodenal polyp,Benign neoplasms gastrointestinal (excl oral cavity),Benign neoplasms gastrointestinal,Gastr,N
1515,7,Gastric polyps,Benign neoplasms gastrointestinal (excl oral cavity),Benign neoplasms gastrointestinal,Gastr,N
1515,8,Graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1515,9,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1515,10,Hydronephrosis,Renal obstructive disorders,Renal disorders (excl nephropathies),Renal,N
1515,11,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1515,12,Inflammation,Inflammations,General system disorders NEC,Genrl,N
1515,13,Leukaemic infiltration,Leukaemias NEC,Leukaemias,Neopl,N
1515,14,Pain in jaw,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
1515,15,Pneumonia klebsiella,Klebsiella infections,Bacterial infectious disorders,Infec,N
1515,16,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1515,17,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1515,18,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1515,19,Systemic candida,Candida infections,Fungal infectious disorders,Infec,N
1516,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1516,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1517,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1517,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1518,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1519,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1519,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1519,3,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
1520,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1521,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1521,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1521,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1521,4,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1522,1,Decreased immune responsiveness,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
1522,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1522,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1522,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1523,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1523,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1523,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1524,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1524,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1524,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1524,4,Polymerase chain reaction positive,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1524,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1525,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1526,1,Retching,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1526,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1527,1,Acute lymphocytic leukaemia,Leukaemias acute lymphocytic,Leukaemias,Neopl,N
1527,2,Cerebral toxoplasmosis,Toxoplasma infections,Protozoal infectious disorders,Infec,N
1527,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1527,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1527,5,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1527,6,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1527,7,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1528,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1528,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1528,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1529,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1529,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1529,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1529,4,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1530,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1530,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1530,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1531,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1531,2,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1532,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1532,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1533,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1534,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1535,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1536,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1536,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1536,3,Impaired work ability,Disability issues,Lifestyle issues,SocCi,N
1536,4,Myalgia,Muscle pains,Muscle disorders,Musc,N
1537,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1538,1,Bronchiolitis,Viral infections NEC,Viral infectious disorders,Infec,N
1539,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1539,2,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1539,3,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1539,4,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1539,5,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1539,6,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1539,7,Bacterial infection,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
1539,8,Blood disorder,Haematological disorders,Haematological disorders NEC,Blood,N
1539,9,Blood disorder,Haematological disorders,Haematological disorders NEC,Blood,N
1539,10,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1539,11,Death,Death and sudden death,Fatal outcomes,Genrl,N
1539,12,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1539,13,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1539,14,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1539,15,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1539,16,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1539,17,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
1539,18,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1539,19,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1539,20,Granulocytopenia,Neutropenias,White blood cell disorders,Blood,N
1539,21,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1539,22,Headache,Headaches NEC,Headaches,Nerv,N
1539,23,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1539,24,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1539,25,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1539,26,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1539,27,Metabolic disorder,Metabolic disorders NEC,Metabolism disorders NEC,Metab,N
1539,28,Metabolic disorder,Metabolic disorders NEC,Metabolism disorders NEC,Metab,N
1539,29,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1539,30,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1539,31,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
1539,32,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1539,33,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1539,34,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1539,35,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1539,36,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1539,37,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1540,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1541,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1541,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1542,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1542,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1543,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1543,2,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1543,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1543,4,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1543,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1544,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
1545,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1546,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1546,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1546,3,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1547,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1548,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1548,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1548,3,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1548,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1548,5,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1549,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1550,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1551,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1552,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1552,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1553,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1553,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1554,1,Cytomegalovirus infection,Cytomegaloviral infections,Viral infectious disorders,Infec,N
1554,2,Disseminated varicella zoster virus infection,Herpes viral infections,Viral infectious disorders,Infec,N
1554,3,Fungaemia,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1554,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1554,5,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
1554,6,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1555,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1555,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1556,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1556,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1556,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1557,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1558,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1559,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1559,2,Head banging,Stereotypies and automatisms,Changes in physical activity,Psych,N
1560,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1560,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1560,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1561,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1562,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1562,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1562,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1563,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1564,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1564,2,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
1564,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1564,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1565,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1565,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1565,3,Gene mutation identification test positive,Gene analyses,Cytogenetic investigations and genetic analyses,Inv,N
1565,4,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
1566,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1567,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1568,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1568,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1568,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1568,4,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1569,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1569,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1570,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1571,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1571,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1571,3,Gastrointestinal toxicity,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
1571,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1571,5,Panniculitis,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
1571,6,Peripheral vascular disorder,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1571,7,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1571,8,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1572,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1573,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1573,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1573,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1573,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1574,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1574,2,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
1575,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1575,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1575,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1576,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1577,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1577,2,Tryptase decreased,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
1578,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1579,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1580,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1580,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1581,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1582,1,Gastrointestinal stoma output increased,Gastrointestinal function diagnostic procedures,Gastrointestinal investigations,Inv,N
1582,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1582,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1583,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1584,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1584,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1584,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1584,4,Headache,Headaches NEC,Headaches,Nerv,N
1584,5,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
1584,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1584,7,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1584,8,Myalgia,Muscle pains,Muscle disorders,Musc,N
1584,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1584,10,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
1585,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
1586,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
1587,1,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1588,1,Product taste abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1589,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1589,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
1590,1,Alanine aminotransferase,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1590,2,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1590,3,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1591,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1592,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1593,1,Headache,Headaches NEC,Headaches,Nerv,N
1593,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1593,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1593,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1594,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1595,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
1595,2,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1595,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1595,4,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
1596,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1597,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1598,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1599,1,Hepatic enzyme abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1600,1,Osteonecrosis of external auditory canal,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1601,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1601,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1601,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1601,4,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
1601,5,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1602,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1603,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
1603,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1604,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1604,2,Muscle disorder,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1604,3,Myopathy toxic,Myopathies,Muscle disorders,Musc,N
1604,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1605,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1605,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1606,1,Chronic myeloid leukaemia transformation,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1606,2,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1606,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1607,1,Bone lesion,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1607,2,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1607,3,K-ras gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
1607,4,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
1607,5,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
1607,6,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1607,7,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1608,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1609,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
1610,1,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
1611,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1612,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1613,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
1613,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1613,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1613,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1613,5,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
1613,6,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1614,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1615,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
1615,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1615,3,Skin wrinkling,Skin dystrophies,Cornification and dystrophic skin disorders,Skin,N
1616,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1616,2,Muscle disorder,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1616,3,Myopathy toxic,Myopathies,Muscle disorders,Musc,N
1617,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1618,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1619,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1619,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1620,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1620,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1620,3,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1620,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1620,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1620,6,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1620,7,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1621,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1622,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1622,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1622,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1622,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1622,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1622,6,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1623,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1623,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1623,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1623,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1623,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1623,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1624,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1624,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1624,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1624,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1624,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1624,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1624,7,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1625,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1625,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1625,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1625,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1625,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1625,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1626,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1627,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1627,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1627,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1627,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1627,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1627,6,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1628,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1628,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1628,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1628,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1628,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1628,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1629,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1629,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1629,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1629,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1629,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1629,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1630,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1630,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1630,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1630,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1630,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1630,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1631,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1631,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1631,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1631,4,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1631,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1632,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1632,2,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
1632,3,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
1632,4,Eye irritation,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,Y
1632,5,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1633,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1634,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1634,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1634,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1635,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1636,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1637,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
1638,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1638,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1639,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
1640,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
1641,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
1642,1,Blast crisis in myelogenous leukaemia,Leukaemias myeloid NEC,Leukaemias,Neopl,N
1642,2,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1642,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1642,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1642,5,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1643,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
1643,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1643,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1643,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1643,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1644,1,Autoimmune hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
1644,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
1644,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1645,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1645,2,Product solubility abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1645,3,Product taste abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1646,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
1647,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1648,1,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1649,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1649,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1650,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1651,1,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1652,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1652,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1652,3,Disseminated intravascular coagulation,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,Y
1652,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1653,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1654,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1654,2,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
1654,3,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
1654,4,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
1654,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1654,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1655,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1656,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1656,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1656,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1656,4,Tunnel vision,Neurologic visual problems NEC,Neurological disorders of the eye,Nerv,N
1657,1,Electrolyte imbalance,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
1657,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1657,3,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
1657,4,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1657,5,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1657,6,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1658,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1658,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1658,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1658,4,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1658,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1659,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
1659,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1660,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1660,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1660,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1660,4,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1661,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1661,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1662,1,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1663,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1663,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1663,3,Laboratory test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1663,4,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
1663,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1663,6,Myalgia,Muscle pains,Muscle disorders,Musc,N
1663,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1663,8,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
1664,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
1665,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1666,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1667,1,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1668,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1668,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1669,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
1670,1,Osteonecrosis of external auditory canal,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1671,1,Osteonecrosis of external auditory canal,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1672,1,Osteonecrosis of external auditory canal,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1673,1,Chronic myeloid leukaemia recurrent,Leukaemias chronic myeloid,Leukaemias,Neopl,N
1674,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1675,1,Bone erosion,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1675,2,Ear pain,Ear disorders NEC,Aural disorders NEC,Ear,N
1675,3,Osteonecrosis of external auditory canal,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1675,4,Otorrhoea,Ear disorders NEC,Aural disorders NEC,Ear,N
1676,1,Osteonecrosis of external auditory canal,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1677,1,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1678,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1679,1,Testicular pain,Testicular and epididymal disorders NEC,Testicular and epididymal disorders,Repro,N
1679,2,Testicular swelling,Testicular and epididymal disorders NEC,Testicular and epididymal disorders,Repro,N
1679,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1680,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1681,1,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1682,1,Osteonecrosis of external auditory canal,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1683,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1684,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1684,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1684,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1684,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1684,5,Headache,Headaches NEC,Headaches,Nerv,N
1684,6,Myalgia,Muscle pains,Muscle disorders,Musc,N
1684,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1684,8,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1685,1,Osteonecrosis of external auditory canal,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1686,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1687,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1687,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1688,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1688,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1689,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1690,1,Product taste abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1690,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1691,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1691,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1691,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1692,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1693,1,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
1693,2,Mental impairment,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
1693,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1693,4,Polymerase chain reaction positive,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1694,1,Adverse reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1695,1,Cytogenetic analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1696,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1696,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1696,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1697,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1697,2,Product availability issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1698,1,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
1699,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1700,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1701,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1701,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1702,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1702,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1703,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1703,2,Urethral cancer,Urinary tract neoplasms malignant NEC,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1704,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1705,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1706,1,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1707,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1707,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1707,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1708,1,Product taste abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1709,1,Rectal cancer,Colorectal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1710,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1710,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1711,1,Brown-Sequard syndrome,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
1711,2,Spinal cord infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1712,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1713,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1713,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1714,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1715,1,Brown-Sequard syndrome,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
1715,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1715,3,Spinal cord infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1716,1,Spinal cord infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1717,1,Brown-Sequard syndrome,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
1717,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1717,3,Spinal cord infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1718,1,Brown-Sequard syndrome,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
1718,2,Spinal cord infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1719,1,Brown-Sequard syndrome,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
1719,2,Spinal cord infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1720,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1721,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1722,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1722,2,Parosmia,Olfactory nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
1722,3,Throat irritation,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1723,1,Brown-Sequard syndrome,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
1723,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1723,3,Spinal cord infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1724,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1724,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1725,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1726,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1727,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1727,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1727,3,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1727,4,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1727,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1727,6,Headache,Headaches NEC,Headaches,Nerv,N
1727,7,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1727,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1727,9,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1727,10,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1728,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1729,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1730,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1730,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1730,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1731,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1731,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1731,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1732,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1732,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1733,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1733,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1733,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1734,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1734,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1735,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1735,2,Product after taste,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1736,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
1736,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1736,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1736,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1736,5,Gastrointestinal toxicity,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
1736,6,Philadelphia chromosome positive,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
1736,7,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1737,1,Death,Death and sudden death,Fatal outcomes,Genrl,N
1738,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1738,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1739,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1739,2,Gastrointestinal stromal tumour,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1740,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1740,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1741,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1741,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1742,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1742,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1743,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1744,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1744,2,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
1745,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1746,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1747,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1747,2,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
1748,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1748,2,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1748,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1748,4,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
1749,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1750,1,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1750,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1750,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1751,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1751,2,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
1752,1,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
1752,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
1753,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1753,2,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
1754,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
1755,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1755,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1755,3,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1755,4,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1755,5,Gastrointestinal motility disorder,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
1755,6,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1755,7,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1756,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1756,2,Change of bowel habit,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
1756,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1756,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1756,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1756,6,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1756,7,Pulmonary arterial hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
1756,8,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1756,9,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1756,10,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1757,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1757,2,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1758,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1758,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1758,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1759,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1759,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1759,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1760,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1761,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1762,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1762,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1763,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1763,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1763,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1763,4,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
1763,5,Myalgia,Muscle pains,Muscle disorders,Musc,N
1763,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1763,7,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1764,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1764,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1765,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1765,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1765,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1766,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1767,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1768,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1768,2,Headache,Headaches NEC,Headaches,Nerv,N
1768,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
1769,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
1769,2,Generalised oedema,Oedema NEC,General system disorders NEC,Genrl,N
1769,3,Malignant hypertension,Accelerated and malignant hypertension,Vascular hypertensive disorders,Vasc,N
1769,4,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1769,5,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1770,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1770,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1770,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1770,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1771,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
1772,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1773,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1773,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
